PATH iOWH032 – v4.0 
13 March 2020 
Title 
A Phase 2a Randomized, Single-Center, Double-Blind, Placebo Con trolled Study 
to Evaluate the Safety and Preliminary Efficacy of Oral iOWH032  Against Cholera 
Diarrhea in a Controlled Human Infection Model 
Protocol Number iOWH032 
DRG-032-PO-2-01-USA 
Name of Principal Investigator: 
 
National Clinical Trial (NCT) Identifier Number:   
[STUDY_ID_REMOVED] 
Sponsor:  
PATH  
Funded by: 
 
 
Protocol Version Number: 
4.0 
REDACTED VERSION 
Version Date: 
13 March 2020 
Confidentiality Statement 
 
This document is confidential and is to be distributed for revi ew only to investigators, potential investigators, consultants,  
study staff, applicable independent ethics committees or instit utional review boards, and applicable regulatory 
authorities.  The contents of this document shall not be disclo sed to others without written authorization from PATH (or 
others, as applicable), unless it is necessary to obtain inform ed consent from potential study participants.  
PATH iOWH032 – v4.0 
13 March 2020  
 
 2   TABLE OF CONTENTS 
  
 
Contents 
TABLE OF CONTENTS ............................................. ...............................................................  2 
LIST OF ABBREVIATIONS AND ACRONYMS ............................ ....................................... 7  
STATEMENT OF COMPLIANCE ....................................... ..................................................... 8  
PROTOCOL SUMMARY .............................................. ............................................................ 9  
1 STUDY RATIONALE ............................................... .................................................. 13  
2 KEY ROLES ..................................................... ........................................................... 14  
3 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE ..................................................... ............................................................... ....... 15  
3.1 iOWH032 General Properties & Pharmacodynamics ................. ................................. 15  
3.2 Summary of Nonclinical Studies of Study Drug .................. ........................................ 16  
3.3 Summary of Clinical Studies of iOWH032 ........................ .......................................... 16  
3.4 Background Information on the Cholera Challenge Model ......... ................................ 18  
3.5 Potential Risks and Benefits .............................. ............................................................... .. 19  
3.5.1 Known Potential Risks ................................... ............................................................... ... 20  
3.5.2 Known Potential Benefits ................................ ............................................................... . 21 
3.6 Overall Development Strategy .................................. ................................................... 21  
4 HYPOTHESIS, OBJECTIVES AND PURPOSE ............................ ............................ 21  
4.1 Study Hypothesis / Hypotheses ................................. ................................................... 21  
4.2 Study Objectives .............................................. ............................................................. 2 1 
5 STUDY DESIGN AND ENDPOINTS .................................... .................................... 22  
5.1 Description of the Study Design ............................... ................................................... 22  
5.2 Study Endpoints ............................................... ............................................................ 22  
6 STUDY ENROLLMENT AND WITHDRAWAL ............................... ....................... 23  
6.1 Participant Inclusion Criteria ................................ ........................................................ 23  
6.2 Participant Exclusion Criteria ................................ ...................................................... 24  
6.3 Strategies for Recruitment and Retention ...................... .............................................. 25  
6.4 Withdrawal from Study ......................................... ....................................................... 25  
6.5 Premature Termination or Suspension of Study .................. ......................................... 26  
PATH iOWH032 – v4.0 
13 March 2020  
 
 3   7 STUDY AGENTS .................................................. ...................................................... 27  
7.1 Study Agent and Control Description ........................... ............................................... 27  
7.2 Challenge Strain Description .................................. ...................................................... 29  
7.3 Study Agents Accountability Procedures ........................ ............................................. 30  
8 STUDY PROCEDURES AND SCHEDULE ................................. ............................. 30  
8.1 Study Procedures/Evaluations .................................. .................................................... 30  
8.2 Laboratory Procedures/Evaluations ............................. ................................................ 31  

PATH iOWH032 – v4.0 
13 March 2020  
 
 4   8.3 Study Schedule ................................................ ............................................................. 3 2 
8.4 Outpatient Clinic Visit 2 (Day 15 ±1) ......................... ................................................. 35  
8.5 Outpatient Clinic Visit 3 (Day 29 ±2) ......................... ................................................. 35  
8.6 Final Follow-up – Visit 4 (Day 180 ±14) ....................... .............................................. 35  
8.7 Unscheduled Visit(s) .......................................... .......................................................... 35  
8.8 Concomitant Medications, Treatments, and Procedures ........... ................................... 36  
8.9 Prohibited Medications, Treatments, and Procedures ............ ...................................... 36  
9 MANAGEMENT OF EXPECTED CHOLERA ILLNESS ........................ ................. 36  
9.1 Clinical Evaluation ........................................... ............................................................ 36  
9.2 Measurement of Diarrhea and Vomitus ........................... ............................................ 36  
9.3 Management of Fluid Loss ...................................... ..................................................... 36  
9.4 Frequency of Vital Signs Assessment ........................... ............................................... 37  
9.5 Fluid Therapy/Hydration ....................................... ....................................................... 37  
9.6 Indications for Antibiotics ................................... ......................................................... 37  
9.7 Indications for Other Concomitant Medications ................. ......................................... 38  
10 ASSESSMENT OF SAFETY .......................................... ............................................ 38  
10.1  Specification of Safety Parameters ............................ ................................................... 38  
10.2  Classification of an Adverse Event ............................ .................................................. 40  
10.3  Time Period and Frequency for Event Assessment and Follow-up .. ........................... 41  
10.4  Reporting Procedures .......................................... ......................................................... 42  
10.5  Study Halting Rules ........................................... ........................................................... 44  
10.6  Safety Oversight .............................................. ............................................................. 4 4 
11 CLINICAL MONITORING ........................................... .............................................. 45  
12 STATISTICAL CONSIDERATIONS .................................... ..................................... 45  
12.1 Statistical and Analytical Plans ......................... ............................................................... . 45 
12.2 Statistical Hypotheses ................................... ............................................................... ..... 45  
PATH iOWH032 – v4.0 
13 March 2020  
 
 5   12.3  Timing of Analyses ............................................ .......................................................... 46  
12.4  Analysis Datasets ............................................. ............................................................ 46  
12.5  Description of Statistical Methods ............................ ................................................... 47  
12.6  Sample Size ................................................... ...............................................................  51 
12.7  Measures to Minimize Bias ..................................... ..................................................... 53  
13 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS ..... 53  
14 QUALITY ASSURANCE AND QUALITY CONTROL ......................... .................. 54  
15 ETHICAL CONSIDERATIONS (AND INFORMED CONSENT).................. .......... 54  
15.1  Ethical Standard .............................................. ............................................................. 5 4 
15.2  Institutional Review Board .................................... ....................................................... 54  
15.3  Informed Consent Process ...................................... ...................................................... 55  
15.4  Exclusion of Women, Minorities, and Children (Special Populatio ns) ....................... 55  
15.5  Participant and Data Confidentiality .......................... .................................................. 55  
15.6  Future Use of Stored Samples .................................. .................................................... 56  
16 DATA HANDLING AND RECORDKEEPING ............................... .......................... 56  
16.1  Data Collection and Data Management Responsibilities .......... ................................... 56  
16.2  Study Records Retention ....................................... ....................................................... 57  
16.3  Protocol Deviations ........................................... ........................................................... 57  
16.4  Publications and Data Sharing Policy .......................... ................................................ 58  
17 FINANCING AND INSURANCE ....................................... ....................................... 58  
18 CONFLICT OF INTEREST POLICY ................................... ...................................... 58  
19 REFERENCES .................................................... ......................................................... 60  
APPENDIX A: PROTOCOL REVISIONS ................................ ............................................. 62  
PATH iOWH032 – v4.0 
13 March 2020  
 
 6   APPENDIX B: SCREENING TESTS ................................... .................................................. 63  
APPENDIX C: SCHEDULE OF STUDY VISITS AND EVALUATIONS .......... ................. 65  
APPENDIX D: CLINICAL SAFETY LABORATORY TOXICITY SCALES ........ ............. 67  
APPENDIX E: REACTOGENICITY AND SOLICITED ADVERSE EVENT TOXICITY  
SCALES ........................................................ ............................................................... ............ 68  
 
   
 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 7 of 69 
  
LIST OF ABBREVIATIONS AND ACRONYMS 
 
AE  Adverse Events ALT  Alanine Aminotransferase AST  Aspartate Aminotransferase CFR  Code of Federal Regulations CFU  Colony-forming Unit CPK  Creatine phosphokinase CRF  Case Report Form CFTR  Cystic Fibrosis Transmembrane Conductance Regulator CYP2C9 Cytochrome P450 2C9 
   
ECG  Electrocardiogram 
eCRF  Electronic Case Report Form 
FDA  Food and Drug Administration GCP  Good Clinical Practices HIV  Human Immunodeficiency Virus ICH  International Council on Harmonisation IND  Investigational New Drug IRB  Institutional Review Board ITT  Intent to Treat MedDRA Medical Dictionary for Regulatory Activities mg  milligram mITT  Modified Intent to Treat mL  milliliter MOP  Manual of Operating Procedures OHRP  Office of Human Research Protections PI  Principal Investigator SAE  Serious Adverse Event SAD  Single Ascending Dose  SOP  Standard Operating Procedure (s) SRC  Safety Review Committee TA  Test Article TEAE  Treatment-emergent Adverse Events ULN  Upper Limit of Normal WHO  World Health Organization    
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 8 of 69 
 STATEMENT OF COMPLIANCE 
The trial will be conducted in accordance with the ICH E6 and t he Code of Federal 
Regulations on the Protection of Human Subjects (45 CFR Part 46 ). The Principal 
Investigator will assure that no deviation from, or changes to the protocol will take place 
without prior agreement from the sponsor and documented approva l from the Institutional 
Review Board (IRB), except where necessary to eliminate an imme diate hazard(s) to the trial 
participants. All personnel involved in the conduct of the stud y will have completed ICH 
GCP training, and that all key investigators will have complete d HSP and RCR training.  
 I agree to ensure that all staff members involved in the conduc t of this study are informed 
about their obligations in meeting the above commitments.   Principal Investigator:    
     Print/Type Name 
  Signed:  ___________________________   Date: _______________     Signature   
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 9 of 69 
 PROTOCOL SUMMARY 
 
Title A Phase 2 a Randomized, Single -Center, Double -Blind, Placebo Controlled 
Study to Evaluate the Safety and Preliminary Efficacy of Oral i OWH032 
Against Cholera Diarrhea in a Controlled Human Infection Model 
Short Title iOWH 032 Efficacy against Cholera  
Protocol 
Number DRG -032-PO-2-01-USA 
IND Number 110,938  (iOWH032)  
NCT Number [STUDY_ID_REMOVED]  
Trial Phase Phase 2 a 
Study Summary This is a single -center, randomized, double -blind, placebo -controlled trial  to 
evaluate the therapeutic efficacy of oral doses of iOWH032 on d iarrhea 
output and clinical symptoms after a cholera challenge.  There will be 24 
study participants challenged in the first cohort and an additi onal 24 study 
participants challenged in the second cohort, pending favorable  results of an 
interim analysis. Participants will be randomized 1:1 to receiv e either 
iOWH032 500 mg every 8 hours for three days or matching placebo . Blinded 
therapeutic dosing will start at the onset of diarrhea or by 48  hours after 
ingesting the challenge inoculum of 106 cfu of V. cholerae  El Tor Inaba strain 
N16961.  The observation and management of cholera diarrhea and  
symptomatology will occur on an inpatient isolation research wa rd over a 
duration of ~11 days, including a three-day course of antibioti cs to treat all 
participants prior to discharge from the inpatient unit.  The f inal study follow-
up visit will be six months after the challenge via phone call.   
Study 
Hypotheses  x iOWH032 will demonstrate reduction in fluid output against chol era 
diarrhea 
x iOWH032 will be safe and well-tolerated 
Objectives Primary Efficacy Objective : 
x To measure the rate and extent of diarrhea following cholera ch allenge, 
in participants treated with iOWH032 compared to placebo 
Primary Safety Objective: 
x To evaluate safety and tolerability of oral doses of iOWH032 co mpared 
to placebo 
Secondary Efficacy Objectives:  
x To evaluate additional measures of efficacy against cholera ill ness 
following cholera challenge, among those randomized to be treat ed with 
iOWH032 versus placebo  
Secondary Safety Objectives: 
x To evaluate tolerability of oral doses of iOWH032 compared to p lacebo 
Exploratory Objectives: 
x To evaluate the pharmacokinetic (pK) properties of iOWH032  
x To evaluate time of cessation of cholera organism in stool afte r challenge  
x To evaluate a decrease for oral rehydration solution (ORS) and/ or 
intravenous (IV) fluid replacement therapy need  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 10 of 69 
 Endpoint(s) 
 Primary  Efficacy Endpoint :  
x Diarrheal stool output rate, defined as the total volume of dia rrheal stools 
(mL, Grade 3 and above) divided by the number of hours between initiation of study product dosing and initiation of antimicrob ial therapy. 
Primary Safety Endpoint: 
x Frequency and incidence of serious adverse events (SAEs) throug hout the 
study 
Secondary Efficacy Endpoints:  
x Proportion of participants with moderate to severe diarrhea fol lowing 
cholera challenge, defined as >3 liters and >5 liters of loose stools , 
respectively, within 48 hours following challenge 
x Attack rate of any diarrhea following cholera challenge, define d as the 
number of participants with either 2 or more loose stools (grad es 3-5) 
totaling > 200 mL, or 1 loose (grade 3-5) stool > 300 mL, respe ctively, 
within 48 hours following challenge 
x Area under the curve (AUC) of diarrheal stool volume between ch allenge 
dose and initiation of antibiotics 
x Density of cholera organisms in post-challenge stool samples me asured in 
stool samples via quantitative stool culture. 
x To evaluate cholera illness in each participant after cholera c hallenge, 
using the following objective parameters:  
1. Duration of diarrheal episode as defined by time to first 
formed stool  
2. Total number of loose (Grades 3-5) stools  
3. Occurrence of fever  
4. Occurrence of vomiting  
Secondary Safety Endpoints: 
x To measure the occurrence of solicited adverse effects during t he three 
days of oral dosing, through 8 hours following the last dose, w hich are 
attributed to iOWH032 and placebo, to include:  
1. Nausea 
2. Abdominal discomfort and pain 
3. Occurrence of abdominal cramps 
4. Occurrence of headache 
5. Occurrence of malaise 
6. Anorexia 
7. Pollakiuria  
8. Micturition urgency 
9. Sinus tachycardia 
10. Increased alertness 
x
 To measure the frequency and incidence of unsolicited adverse e ffects up 
to 28 days after the last dose. 
 Exploratory Endpoints:  • To determine plasma levels of iOWH032 7±1 hours after the fir st and last 
dosing in all participants 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 11 of 69 
 x Time (hours) to cessation of detectable cholera in stool, defin ed as the 
time of the first sample negative via quantitative culture, aft er which all 
following samples are also negative for cholera. 
x ORS and/or IV fluid replacement measured in liters  
 
Description of 
Study Agent Study Therapeutic:  iOWH032  is a synthetically ma nufactured small molecule 
designed to inhibit the cystic fibrosis transmembrane conductan ce regulator 
(CFTR) chloride channel. iOWH032 is a lipophilic product which is poorly 
soluble in aqueous solutions. iOWH032 is available as 250 mg ta blets. 
Placebo:  Matching placebo tablets. 
Challenge Agent:  Freshly-harvested, wild-type V. cholerae  El Tor Inaba strain 
N16961 will be the challenge agent. Strain N16961 will be deliv ered at 106 
colony forming units (cfu), suspended in 30 mL of sodium bicarb onate 
solution (~1.3% NaHCO 3). 
Study and 
Participant Duration The entire study duration is anticipated to be approximately 8-9 months, 
inclusive of screening period up to 85 days prior to enrollment , at least 28 
days of scheduled follow-up after challenge and a six-month pho ne follow-up. 
Each participant is anticipated to be in the study for a period  of 6 months 
following administration of the challenge dose.   
Study 
Population  Healthy adults , 18-44 years old , inclusive. Participants  with Blood type O 
(carrying a higher risk for Cholera Gravis vs. Non-O) will not be preferentially 
selected, although randomization to treatment will be stratifie d by blood type 
status (O vs Non-O).  
Number of 
Participants  48 participants will be enrolled in the study, split into two c ohorts of 24 each. 
24 total (12 in each cohort) will receive the test product (iOW H032) and 24 
total (12 in each cohort) will receive placebo in a randomized double-blind 
fashion.  Up to 5 volunteers will be admitted to the contained units as 
alternates to ensure a complete cohort, but discharged prior to  challenge.  
Randomization  Participants  will be randomized in a 1:1 ratio in each of two sequential 
cohorts to receive either iOWH032 or placebo. The participants will be 
stratified based on blood type so that there are equivalent num bers of 
volunteers with blood type O in each study arm. A randomization  list will be 
prepared allocating participant identification numbers to the s tudy group. 
The randomization scheme will be provided to the unblinded rese arch 
pharmacist(s).  
Bacteriological 
Assessments  All loose stools (grade 3 and higher) will be weighed/measured for volume, 
and graded.  A maximum of two stool samples daily will be exami ned for the 
presence of V. cholerae  prior to receipt of antibiotics. Following antibiotics, if 
a subject cannot produce stool, a rectal swab will be performed  every 12 
hours in order to fulfillment of discharge criteria.  
   
Sample Size  Study enrollment will proceed in two stages, with 24 participants  randomized 
1:1 to iOWH032 vs. placebo within each stage. Following complet ion of the 
first stage, an interim analy sis of the primary efficacy endpoi nt will be 
conducted and the 2nd cohort will be enrolled, provided the study does not 
demonstrate either overwhelming efficacy or evidence of futilit y based on the 
results of the first cohort. A simulation-based approach was us ed to select 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 12 of 69 
 boundaries for interim efficacy and futility, and to compute st udy power and 
maintain overall type I error at the nominal level. Using a str atified Wilcoxon 
rank-sum test (Van Elteren test) to compare diarrheal stool out put rate 
between study arms in a group-sequential inferential framework,  a total of 48 
participants split equally between study arms provides 90% powe r to observe 
a 50% reduction in the cumulative diarrheal stool volume, based  on prior data 
of placebo-treated participants challenged with the same strain  as used in this 
study.  
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 13 of 69 
 1 Study Rationale 
This clinical trial is designed to be a Phase 2a, which will do cument the preliminary efficacy of oral 
doses of iOWH032 in diminishing the severity of illness of chol era, using a well-established human 
challenge model. 
 
1.1  Schematic of Study Design  
 
In Cohort 1, 24 eligible healthy male and female participants w ill be randomized 1:1 to be assigned to 
the iOWH032 (active treatment) or placebo. Following a favorabl e assessment of iOWH032 in an 
interim analysis, Cohort 2 will include an additional 24 health y participants randomized 1:1 to 
iOWH032 or placebo. All participants will be challenged with 106 cfu of V. cholerae  El Tor Inaba strain 
N16961. Blinded treatment will begin at the onset of (any) diar rhea symptoms or 48 hours after 
challenge, whichever is sooner, and consists of three oral dose s per day, over three days.  The dosage 
of iOWH032 is 500 mg (two 250 mg tablets) per dose.   
A 3-day course of antimicrobial therapy will be initiated at ap proximately 4 days post challenge or 
sooner if indicated.  The Principal Investigator will be able t o initiate antibiotics upon severe cholera 
definition being satisfied. The blinded study treatment will co ntinue during antimicrobial therapy. 
For participants that remain asymptomatic, the last dose of iOW H032 and first dose of antibiotic will 
be separated by 1-2 hours. Discharge from the Clinical Research  Unit will be contingent upon each 
participant meeting all the following criteria:  
x 3 consecutive stool cultures that are negative for growth of vi brios (with each culture 
separated by at least 12 hours) 
x The absence of moderate or higher grade objective reactogenicit y (diarrhea, fever, and 
vomiting) for at least 12 hours prior to discharge 
x The completion of a 3-day course of antimicrobial (preferred ag ent, ciprofloxacin, 500 mg 
twice daily for 3 days) therapy 
No. 
Participants  Treatment Group  Treatment duration  Challenge inoculum  
Cohort 1  
12 iOWH 032 3 days  N16961 at 106 cfu 
12 Placebo  3 days  N16961 at 106 cfu 
Cohort 2  
12 iOWH032  3 days  N16961 at 106 cfu 
12 Placebo  3 days  N16961 at 106 cfu 
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 14 of 69 
 Principal Investigator   
   
Pharmaron CPC Inc. 
 
Co-Investigator   
Center for Vaccine Development University of Maryland School of Medicine 
 
 
 
University of Maryland School of Medicine 
 
Medical Officer   
PATH 
 
PATH Study Statistician   
PATH 
 
Project Coordinator   
PATH 
 
 
 
Clinical Site Monitor   
The Total Approach Inc. 
  
Drug M anufacturer  Representative    
Syngene International  
 
Clinical Microbiology Laboratory  
 Center  for Vaccine Development  and Global Health  
Clinical Microbiology Laboratory 
 
Challenge Site  Pharmaron CPC, Inc.  
 
Data Management  Pharmaron CPC, Inc.  
 
Ethics Committee  Advarra  IRB 
6940 Columbia Gateway Dr.  #110, 
Columbia, MD 21046  
 
  2 KEY ROLES 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 15 of 69 
  
3 INTRODUCTION: BACKGROUND INFORMATION AND 
SCIENTIFIC RATIONALE 
Cholera is an acute gastrointestinal illness caused by the inge stion of food or water contaminated with 
the Gram-negative bacillus V. cholerae . Infection is associated with copious, toxin-mediated, watery 
diarrhea and can result in rapid and fatal dehydration if untre ated. It remains a public health problem 
among underprivileged populations in many developing countries,  and visitors to such areas. The 
cholera toxin (CT) of V. cholerae  acts through the pathophysiologic mechanism of stimulation of the 
cystic fibrosis transmembrane conductance regulator (CFTR) chlo ride ion channel. The investigational 
new drug iOWH032 is being developed as an oral therapy for the treatment of acute secretory 
diarrhea in adults and children. While oral rehydration therapy  (ORT) is a safe and cost-effective 
treatment for acute secretory diarrhea, it does not reduce diar rheal output, which may lead to poor 
outcome, compliance and acceptance of this therapy. An antisecr etory agent that reduces 
dehydration, provides rapid symptomatic relief, and speeds reco very with a short course of therapy 
(e.g., two to three days) is expected to improve patient outcom es and compliance. While iOWH032 is 
intended as a treatment for acute secretory diarrhea in epidemi c conditions of both adult and 
pediatric populations, iOWH032 will first be evaluated in adult s in this Phase 2a study prior to a 
potential age-descending trial.  
3.1 iOWH032 General Properties & Pharmacodynamics 
iOWH032 is a synthetically manufactured small molecule designed  to inhibit CFTR, a cyclic 
adenosine monophosphate (cAMP)-activated chloride ion (Cl−) channel expressed in epithelial cells 
of mammalian airways, intestine, pancreas, skin, and testis. iO WH032’s ability to inhibit the CFTR 
chloride channel was demonstrated in vitro using T84 colon carc inoma cells and Chinese hamster 
ovary (CHO) cells expressing human CFTR. The 50% inhibitory con centration in these assays ranged 
from 2-11 PM. iOWH032’s activity in vivo was demonstrated in two disease m odels: the mouse 
closed-loop model and cecectomized rat open-loop model. The CFT R chloride channel in the 
gastrointestinal (GI) tract has both intracellular and extracel lular (luminal) inhibitor sites. It is 
hypothesized that the inhibitory activity, and hence the pharma codynamic response of iOWH032, 
will most likely be driven by GI lumen concentrations rather th an plasma concentrations. The 
activity at the extracellular site will depend directly on the concentration in solution within the GI 
tract. 
iOWH032 has a molecular weight of 545.18. It has a phenolic moi ety and behaves as a weak acid 
(experimental pKa 7.84). It is a lipophilic molecule and is exp ected to be freely permeable across the 
lipid layer of biological membranes as demonstrated both by the  parallel artificial membrane 
permeability assay and the use of Heterogeneous Human Epithelia l Colorectal Adenocarcinoma cell 
line (Caco-2) cell line monolayers. It is also confirmed that i OWH032 was not a substrate for the 
efflux transporter, P-glycoprotein (efflux ratio < 2). iOWH032 does, however, show limited solubility 
(< 1 μM at pH 7.4), especially in acidic conditions. Its solubi lity increases in the presence of 
simulated fasted intestinal fluid (7.5 μM). 
 

PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 16 of 69 
 The plasma half-life of iOWH032 administered orally in rats and  dogs was in the range of 1 to 3 
hours with maximum plasma concentrations (C max) observed at approximately 1 to 2 hours post 
dose. The absolute bioavailability of an oral dose of 5 mg/kg w as 38.1% in rats, and bioavailability of 
an oral dose of 3 mg/kg was 81.2% in dogs, showing absorption a nd bioavailability from the oral 
route. In vitro studies showed iOWH032 to be > 99% protein-boun d in human, rat, and dog plasma. 
The clearance of iOWH032 was low relative to hepatic blood flow , with values of 0.452 L/hr/kg in 
rats and 0.096 L/hr/kg in dogs. However, despite this low clear ance in both species, the 
corresponding half-lives of iOWH032 were short, 0.4 hours and 3 .18 hours in rats and dogs, 
respectively, most likely due to the low volume of distribution . 
3.2 Summary of Nonclinical Studies of Study Drug  
The toxicology program included genotoxicity studies, acute (si ngle-dose) and repeat-dose studies 
up to 14 days in duration, and reproductive toxicology studies in rats and rabbits. Animals received 
up to 2,000 mg/kg/day and there were no major toxicity findings  with potential clinical significance. 
iOWH032 was shown in an in vitro study to be a potent inhibitor  of Cytochrome P450 2C9 (CYP2C9) 
(IC 50 0.08 μM) and, to a lesser extent, CYP2C19 (IC 50 24 μM). Concomitant administration of 
iOWH032 with drugs metabolized by CYP2C9 should be avoided. Thi s includes warfarin, phenytoin, 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and other drugs described in the Appendix F. 
However, significant drug interactions in patients are not anti cipated because of the short duration 
of treatment (≤ 3 days). 
In the in vitro human ether-à-go-go–related gene (hERG) assay, the IC 20 for the inhibitory effect of 
iOWH032 on hERG potassium currents was 1.87 μM and the IC 50 was estimated to be > 4.95 μM, 
approximately 150-fold higher than the unbound concentration (C max(unbound) = 33.6 nM) of iOWH032 
found in humans dosed with 500 mg every 8 hours. Cardiac safety  was evaluated in telemetry- 
instrumented dogs in a cardiovascular safety pharmacology study  and by monitoring ECGs during 
the repeat-dose toxicology study in dogs. No adverse effects of  iOWH032 were observed on any 
cardiac parameter (blood pressure, heart rate, ECG including QT c) at doses up to 1000 mg/kg. In the 
clinical setting, protein binding is also expected to be high ( 99.79% in humans, based on in vitro 
studies) and, therefore, the free (unbound) concentration of iO WH032 in vivo is expected to be 
much lower than the concentration required to significantly inh ibit the hERG potassium channel in 
vitro. 
3.3 Summary of Clinical Studies of iOWH032  
iOWH032 has been administered to 72 healthy adult volunteers in  two Phase 1 studies conducted in 
the United States, and was  found to be generally well-tolerated  at single doses ranging from 30 mg 
to 1000 mg, and when administered for 3 days at doses ranging f rom 100 mg every 12 hours to 500 
mg every 8 hours.  A two-part bridging pharmacokinetic (DDP-CFT -PO-201) study was performed 
May-October 2013 in eight (8) healthy adult volunteers and twel ve (12) adult male cholera patients 
in Bangladesh ([STUDY_ID_REMOVED]).  
3.3.1 iOWH032 Human Phamacokinetics Data  
In the single ascending dose (SAD) study, doses of iOWH032 admi nistered under fasted conditions 
exhibited absorption that was dose-independent with a median ti me of maximum plasma 
concentration (T max) of 5 to 6.5 hours. Exposure to iOWH032 [C max and AUC 0-inf] increased over the 
single-oral-dose range of 30 mg to 1000 mg in a less-than-dose- proportional manner. This was most 
pronounced at doses up to 300 mg; exposure at doses of 300 mg t o 1000 mg appeared to increase 
in an approximately dose-proportional manner, but proportionali ty could not be confirmed 
statistically. Elimination half-life was similar across the tes ted dose range and was independent of 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 17 of 69 
 feeding status. However, there was a significant increase in iO WH032 exposure parameters [C max: 
3.85-fold and AUC 0-inf: 3.67-fold higher] when 500 mg iOWH032 was administered with a  high-fat 
breakfast. The highest exposure to iOWH032 in this study was ob served when 500 mg iOWH032 was 
administered with a high-fat breakfast [geometric mean: AUC 0-inf 124,000 ng·hr/mL; C max 7270 
ng/mL]. 
In the multiple ascending dose (MAD) study, the median T max ranged from 4 to 6 hours following 
single-dose administration on Day 1 and from 3.00 to 4.00 hours  following multiple-dose 
administration on Day 4. Following T max on Day 4, the iOWH032 plasma concentrations declined in a 
mostly monophasic manner. The elimination half-life of iOHW032 (10.3 to 11.7 hours) was 
independent of the administered dose. After single doses, geome tric mean C max values ranged from 
2000 ng/mL (100 mg every 12 hours) to 5210 ng/mL (500 mg every 12 hours) and geometric mean 
AUC tau values ranged from 14,900 ng·h/mL (100 mg every 12 hours) to 4 3,200 ng·h/mL (500 mg 
every 12 hours). After multiple dosing, geometric mean C max values ranged from 2520 ng/mL (100 
mg every 12 hours) to 8730 ng/mL (500 mg every 8 hours) and geo metric mean AUC tau values 
ranged from 23,000 ng·h/mL (100 mg every 12 hours) to 72,000 ng ·h/mL (500 mg every 12 hours). 
Regression analysis indicated that iOWH032 plasma exposure as m easured by AUC tau indicated a 
less-than-proportional increase over the studied dose range. 
Human metabolism of iOWH032 was evaluated in vivo using liquid chromatography tandem mass 
spectrometry, demonstrating the major plasma and urinary metabo lites to be a hydroxylated 
product with its glucuronide also being in urine but not in pla sma. Thus, it would appear that in vivo, 
the major metabolite of iOWH032 circulating in human plasma is also the same as that circulating in 
rat plasma. 
3.3.2  iOWH032 Human Safety Data  
In the SAD study, the most common adverse event (AE) was pollak iuria (extraordinary daytime 
urinary frequency). In the 30 mg dose group, 4 of 6 participant s, all who received active drug and 
none who received placebo, reported pollakiuria beginning 3 to 6 hours following receipt of the 
single dose and persisting for 19 to 30 hours. Three of these s ame participants also reported 
micturition urgency, and two reported an increase in stool freq uency (3 formed stools in one day 
rather than their usual 1 formed stool). All adverse events wer e rated as mild in severity and 
resolved spontaneously. Repeated urinalyses (including urine sp ecific gravities), urine cultures, 
serum electrolytes, blood urea nitrogen (BUN), creatinine, and complete blood counts were all 
normal throughout the period of time the participants were symp tomatic. Plasma concentrations of 
iOWH032 in these 4 participants ranged from approximately 400–9 00 ng/mL. No urinary symptoms 
were reported by participants enrolled in the 300, 500, or 1000  mg dose cohorts in the SAD portion 
of the study. One participant in the food effects portion of th e study reported pollakiuria following 
his receipt of the 500 mg dose in both the fed and fasted porti ons of the study. This participant 
reported onset of symptoms beginning approximately 4 hours afte r dosing in each treatment period 
and on both occasions, reported being symptomatic for approxima tely 4 days. As observed in the 30 
mg dose cohort, repeated urinalyses (including urine specific g ravities), urine cultures, serum 
electrolytes, BUN, creatinine, and CBCs were normal and the par ticipant’s symptoms resolved 
spontaneously. This participant’s ma ximum iOWH032 plasma concen trations were 6492 ng/mL in 
the fed state and 3432 ng/mL in the fasting state. 
One 19-year-old female with no history of cardiovascular diseas e experienced isolated, 
asymptomatic premature ventricular contractions (PVCs) at 2 and  3 hours following a single dose of 
100 mg of iOWH032. ECGs that were obtained at screening and pre -dose were normal except for 
intermittent sinus tachycardia. On telemetry during the next 24  hours, she persisted in having 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 18 of 69 
 isolated asymptomatic PVCs without any accompanying symptoms of  palpitations, chest pain, or 
dizziness. A thorough cardiac evaluation by a board-certified c ardiologist revealed a normal cardiac 
exam, normal stress echocardiogram, normal ECG, and no evidence  of structural cardiac disease. 
In the MAD study, the most frequently occurring treatment-emerg ent adverse events (TEAEs) 
reported in 2 or more participants overall were application sit e irritation (at the site of 
electrocardiogram patches) (11/40, 27.5%), sinus tachycardia (3 /40, 7.5%), catheter site pain (2/40, 
5.0%), decreased appetite (2/40, 5.0%), and headache (2/40, 5.0 %). Treatment-emergent sinus 
tachycardia and decreased appetite were not reported in partici pants who received placebo. 
Three mild TEAEs of sinus tachycardia were reported by a single  participant in each of the following 
3-dose cohorts: 300 mg iOWH032 every 8 hours, 500 mg iOWH032 ev ery 12 hours, and 500 mg 
iOWH032 every 8 hours. No clinically significant changes in blo od pressure or other ECG parameters 
accompanied the tachycardia. Two of these participants had the maximum iOWH032 exposures in 
their dose cohorts and had close to the maximum overall exposur e of all participants during the 
time of their sinus tachycardia; 1 of the 2 participants experi enced an accompanying TEAE of 
increased alertness and the other participant reported no accom panying symptoms. The third 
participant who had a TEAE of sinus tachycardia reported an acc ompanying symptom of a 
“stimulated feeling” and had iOWH032 exposures that approximate d the median for his dose cohort 
and also for all participants. One participant reported a TEAE of palpitations that was 
unaccompanied by tachycardia. A slight upward trend in average pulse rate change from baseline 
was observed with increasing iOWH032 plasma concentration, but it was not statistically significant. 
Mean systolic blood pressure decreased by approximately 10 mmHg  in the 300-mg and 500-mg 
iOWH032 every-8-hour dose cohorts compared to the pooled placeb o group, beginning 
approximately 1 hour following receipt of Dose 1 and persisting  until approximately 112 hours after 
Dose 1 (approximately 40 hours after the receipt of Dose 10 of iOWH032). None of the individual 
decreases were considered clinically important decreases in sys tolic blood pressure and thus were 
not reported as adverse events. 
In the PK bridging study (Bangladesh, DDP-CFT-PO-201), one SAE was reported in a patient with 
cholera. This SAE of elevated serum creatine kinase/creatine ph osphokinase was deemed unlikely 
related to the drug, as there were no clinically relevant featu res or changes in ECG parameters that 
were found to be associated.  No treatment was provided to the participant in response to the 
event. No action was taken with regards to the study drug due t o the event.  
3.4 Background Information on the Cholera Challenge Model 
Cholera continues to be a major public health problem in nearly  all developing countries including 
the Western hemisphere, afflicting both children and adults, an d is an endemic disease in over 100 
countries of the world. There are over 200 serogroups of choler a, based on the polysaccharide O-
antigen. Epidemic cholera is associated with the O1 and, more r ecently, O139 serogroups. The O1 
serogroup is further classified by biotype, classical or El Tor , and within this biotype by serotype, 
Ogawa or Inaba. Carefully conducted human challenge studies hav e been used to demonstrate the 
efficacy of cholera vaccine candidates. Pioneered at the Univer sity of Maryland, Baltimore (UMB), 
Center for Vaccine Development (CVD), cholera challenge models have been safely and successfully 
used for over 40 years. Investigators at CVD developed a challe nge model using freshly harvested V. 
cholerae  El Tor Inaba strain N16961.  Previous studies demonstrated a c lear dose-response (Table 1) 
and indicated that a 106 cfu challenge dose of freshly harvested V. cholerae  strain N16961 produced 
consistent disease (Table 2). 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 19 of 69 
 Table 1: Clinical and bacteriological responses of healthy volunteers  to various doses of freshly harvested V. 
cholerae  El Tor Inaba strain N16961  
Inoculum  Attack 
Rate for 
Diarrhea  Mean 
Incubation 
(Hours)  Mean 
Diarrheal 
Stool 
Volume 
(Liters)  Mean 
Number 
Diarrheal 
Stools 
(per day)  Vomiting  Fever  Positive 
Stool 
Culture  
103 4/6 33 0.9 5.1 0/6 0/6 6/6 
104 4/5 36 1.1 6.5 0/5 0/5 4/5 
105 3/5 18 3.1 15 0/5 0/5 4/5 
106 9/10 25 3.2 12.9 2/10 2/10 10/10  
 
Table 2: Diarrheal attack rates with freshly harvested V. 
cholerae  El Tor Inaba strain N16961, across multiple 
challenge studies 
CVD Protocol  Inoculum  Attack Rate for 
Diarrhea  
3002A 0.62 x106 5/5 
3005B 1.0 x106 4/5 
5009 1.9 x106 6/8 
5011 2.0 x106 5/7 
5013 1.4 x106 7/8 
5025 2.2 x106 9/9 
6001 2.3 x106 6/7 
6005 1.98 x106 10/11 
6011 1.74 x106 6/6 
7002 1.74 x106 7/7 
7004 1.79 x106 6/8 
9003 1.0 x106 7/8 
11002 1.07 x106 13/13 
 TOTAL 91/102 (89%) 
It is intended that 106 cfu challenge doses of freshly harvested V. cholerae  strain N16961 will be 
administered to study participants in this clinical trial, to a llow for a preliminary assessment of the 
efficacy of iOWH032. 
3.5 Potential Risks and Benefits 
No benefits are expected to participants for their participatio n in this research study.  The study 
screening visit will be free of charge, but that if any clinica l abnormalities are noted during that visit 
that participants will be referred to their own physician for f urther follow-up. 
There is the potential for some therapeutic efficacy against ac ute secretory diarrhea with oral doses 
of iOWH032, but this has not been proven.  Participants that un dergo challenge with cholera should 
expect to have diarrhea, in some cases the diarrhea can be seve re. Cholera illness may also be 
associated with nausea, vomiting, abdominal cramping or discomf ort, loss of appetite, muscle aches, 
and tiredness. The electrolyte losses with the secretory diarrh ea may result in cardiac conduction 
abnormalities, if uncorrected. Intravascular volume losses with  diarrhea can be associated with 
postural hypotension, shock, and death, if uncorrected. In this  study, participants will be closely 
monitored to detect and prevent such effects, with rescue treat ment readily provided (See section 
9). 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 20 of 69 
 3.5.1 Known Potential Risks 
Oral doses of iOWH032. Doses of 500 mg administered every 8 hou rs for 10 consecutive doses (3 
days plus a single dose on Day 4) have generally been well tole rated in the limited studies that have 
been performed. Potential known AEs of iOWH032 are pollakiuria,  micturition urgency, sinus 
tachycardia and increased alertness.  There may be other unknown risks, discomforts, or side effects 
from iOWH032.  Any significant adverse events, which are deemed  possibly related to iOWH032, will 
be disclosed, as appropriate. 
Challenge with V. cholerae  strain N16961. The intended dose of 106 cfu is expected to elicit acute 
watery diarrhea within 18-48 hours of ingestion; about 20% are expected to have severe cholera. 
Persons that are blood group O are known to be more likely to h ave severe cholera.  Nausea or 
vomiting, abdominal cramping or discomfort, and loss of appetit e are also common symptoms that 
accompany cholera. Fever is a rarer symptom with cholera. The s igns of severe dehydration can 
involve dry mouth, decreased urine, thirst, cold clammy skin, h ypotension, lethargy, stupor, and 
muscle cramping. The complications of too much fluid lost throu gh excessive diarrhea include 
hypoglycemia (low blood sugar), acidosis, kidney failure, pulmo nary edema (fluid in lungs), 
arrhythmia (heart rhythm abnormalities), coma, and death. Antic ipated dehydration will be 
managed with aggressive fluid rehydration (oral and/or intraven ous) with potassium repletion. Early 
antibiotic therapy will be provided to participants that achiev e severe cholera illness; otherwise all 
participants will be treated with antibiotics at approximately 4 days post-challenge. It is expected 
that shedding will occur in the stool; however, transmission fr om person to person is mitigated by 
housing the participants on the Clinical Research Unit until th ey meet the protocol discharge criteria. 
Participants will be counselled about use of standard hygiene p ractices (i.e., hand washing with soap 
and water after defecation), to decrease the likelihood of tran smission of the strain person to 
person.   
Risk of Allergic Reaction. There is a very rare risk for an all ergic reaction to the study drug iOWH032, 
the placebo, the challenge inoculum, or the antibiotic. Allergi c reactions generally can range from 
mild (for example, skin rash, itching, swelling, or numbness) t o severe (for example, low blood 
pressure, difficulty breathing, shock, heart arrest, or death).  The symptoms of a mild allergic 
reaction typically go away without treatment, but some cases ma y require treatment with 
antihistamines or steroids (medications used to treat allergic reactions). In the case of more severe 
allergic reactions such as shock, immediate and intensive medic al treatment is necessary. Although 
the risk of an allergic reaction is very small, epinephrine, an tihistamines, and other equipment will 
be available to treat anaphylaxis or immediate hypersensitivity  reactions. 
Risk with Pregnancy. The study drug iOWH032 has not been evalua ted in pregnant women. 
Therefore, the risk to the unborn fetus or pregn ant mother is u nknown. Cholera infection in a 
pregnant woman can harm the fetus. All female study participant s will be tested for pregnancy, 
during screening and one day before the challenge. To be eligib le, female study participants must be 
using a highly effective form of contraception for the duration  of the trial and the four weeks before 
and after the challenge.  If a pregnancy occurs between challen ge and 28 days post-challenge, it will 
be reported immediately (within 24 hours of identification) to the sponsor’s medical officer. A 
pregnancy is reported as an AE or SAE only when there is suspic ion that the investigational product 
may have interfered with the effectiveness of contraception or there was a serious complication in 
the pregnancy including a spontaneous abortion or an elective t ermination for medical rationale, or 
a birth defect in the baby. 
Risk with Blood Draws. Blood will be drawn at several times dur ing the study and may also be 
performed to help manage the diarrheal illness. The drawing of blood may cause pain, bruising, 
feeling faint, fainting, needle site infections, swelling, and rarely other infections.  Bruising at the site 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 21 of 69 
 of blood drawing can be prevented by applying pressure for seve ral minutes.  To reduce the risk of 
infection, the skin site is prepared with an alcohol wipe and s terile technique is used.  
Rectal swab (if a stool sample is not provided). Rectal swabs m ay be performed as part of the 
requirement for discharge criteria (i.e., three sequential nega tive stool cultures separated by 12 
hours). The rectal swab may cause the sensation of rectal press ure, but is not painful. 
Risks to Confidentiality. Personal health information will be c ollected as a part of this study and 
efforts will be made to maintain confidentiality. There is a sm all risk of loss of confidentiality that an 
unauthorized person may gain access to viewing the research rec ords. In order to maintain 
confidentiality, all study records will be stored in a secure l ocation, such as a locked office and/or 
locked cabinet. Electronic data will be password-protected.  St udy records and specimens obtained 
will be coded.  Research records will only be shared with autho rized personnel and only in 
connection with carrying out the obligations relating to the st udy. Every effort will be made to keep 
the records as confidential as possible, within the limits of t he law. 
3.5.2 Known Potential Benefits  
This is a healthy volunteer study which does not provide any gu arantee of benefit to the 
participants. The benefit is largely the scientific knowledge t o be gained from the study.  
3.6  Overall Development Strategy  
To predict the usefulness of iOWH032 as a public health tool in  the treatment of cholera, PATH 
proposes to first determine the degree of protection provided a gainst moderate to severe diarrheal 
disease with V. cholerae  using a human challenge study as a Phase 2a trial, before proc eeding to 
field studies.  While a cholera challenge study will not answer  all of the questions regarding the use 
of an antisecretory drug in the field, it will provide an answe r on the degree of reduction of diarrheal 
disease under these optimal conditions.  If it is not efficacio us in the challenge model it is unlikely to 
be effective in the field.  Therefore, a positive result in the  challenge model would justify further 
field efficacy trials for fluid reduction in cholera.  If efficacy is found in the challenge study, the next step is t o perform field trials in areas where 
cholera occurs. Our goal is to achieve US approval by submittin g a New Drug Application to the FDA, 
followed by prequalification by the World Health Organization ( WHO) to support product acquisition 
by UNICEF and other humanitarian agencies for its distribution to low- and middle- income 
countries.  
 
4 HYPOTHESIS, OBJECTIVES AND PURPOSE 
4.1 Study Hypothesis / Hypotheses 
x iOWH032 will demonstrate reduction in fluid output against chol era diarrhea  
x iOWH032 will be safe and well-tolerated 
 
4.2  Study Objectives 
4.2.1 Primary Efficacy Objective 
x To measure the rate and extent of diarrhea following cholera ch allenge, in participants treated 
with iOWH032 compared to placebo 
4.2.2 Primary Safety Objective: 
x To evaluate safety of oral doses of iOWH032 compared to placebo  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 22 of 69 
 4.2.3 Secondary Efficacy Objectives: 
x To evaluate additional measures of efficacy against cholera ill ness following cholera challenge, 
among those randomized to be treated with iOWH032 versus placeb o  
4.2.4 Secondary Safety Objective: 
x To evaluate tolerability of oral doses of iOWH032 compared to p lacebo 
4.2.5  Exploratory Objectives: 
x To evaluate the pharmacok inetic (pK) propert ies of iOWH032 
x To evaluate time of cessation of cholera organism in stool afte r challenge  
x To evaluate a decrease for ORS and/or IV fluid replacement ther apy need 
5 STUDY DESIGN AND ENDPOINTS 
 
5.1 Description of the Study Design 
 
This is a single-center, randomized, double-blind, placebo-cont rolled challenge and therapeutic trial 
assessing diarrheal output and clinical symptoms when given eit her placebo or oral iOWH032 500 
mg (two 250 mg tablets) every 8 hours for three days starting a t the onset of any diarrhea (upon first 
Grade 3-5 stool, regardless of volume) stool or 48 hours after ingesting an inoculum of V. cholerae  
N16961, whichever is sooner, and consists of three oral doses p er day, over three days.     
 
Test Article (TA) N Dose 
iOWH032 24 500 mg (two 250 mg tablets) every 8 hours for 3 days 
with meals 
Placebo  24 Two  placebo tablet s every 8 hours for 3 days with meals  
Challenge  48 106 CFU Vibrio cholerae N16961, once on challenge day  
 
 
5.2  Study Endpoints 
5.2.1 Primary Efficacy Endpoints 
x Diarrheal stool output rate, defined as the total volume of dia rrheal stools (mL, Grade 3 and 
above) divided by the number of hours between initiation of stu dy product dosing and 
initiation of antimicrobial therapy  
5.2.1 Primary Safety Endpoint: 
x Frequency and incidence of serious adverse events (SAEs) throug hout the study 
5.2.2 Secondary Efficacy Endpoints: 
x Proportion of participants with moderate to severe diarrhea fol lowing cholera challenge, 
defined as >3 liters and >5 liters of loose stools, respectivel y, within 48 hours following 
challenge  
x Attack rate of any diarrhea following cholera challenge, define d as the number of participants 
with either 2 or more loose stools (grades 3-5) totaling > 200 mL or 1 loose (grade 3-5) stool > 
300 mL, respectively, within 48 hours following challenge 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 23 of 69 
 x Area under the curve (AUC) of diarrheal stool volume between ch allenge dose and initiation of 
antibiotics 
x Density of cholera organisms in stool samples measured in  stoo l samples via quantitative stool 
culture 
x To evaluate cholera illness in each participant after cholera c hallenge, using the following 
objective parameters:  
1. Duration of diarrheal episode as defined by time to first forme d stool  
2. Total number of loose (Grades 3-5) stools  
3. Occurrence of fever  
4. Occurrence of vomiting  
5.2.3 Secondary Safety Endpoints: 
x To measure the occurrence of solicited adverse effects during t he three days of oral dosing, 
through 8 hours following the last dose, which are attributed t o iOWH032 and placebo, to 
include:  
1. Nausea 
2. Abdominal discomfort and pain 
3. Occurrence of abdominal cramps 
4. Occurrence of headache 
5. Occurrence of malaise 
6. Anorexia 
7. Pollakiuria  
8. Micturition urgency 
9. Sinus tachycardia 
10. Increased alertness 
x To measure the frequency and incidence of unsolicited adverse e ffects up to 28 days after the 
last dose. 
5.2.4  Exploratory Endpoints  
x To determine plasma levels of iOWH032 7±1 hours after the first  and last dosing in all 
participants 
x Time (hours) to cessation of detectable cholera in stool, defin ed as the time of the first sample 
negative via quantitative stool culture, after which all follow ing samples are also negative for 
cholera. 
x ORS and/or IV fluid replacement in measured liters  
6 STUDY ENROLLMENT AND WITHDRAWAL 
 
6.1 Participant Inclusion Criteria  
1. Willing and able to unders tand and provide written informed con sent 
2. Healthy male and female adults, age 18 to 44 years (inclusive),  without clinically significant 
medical history, physical or clinical laboratory abnormalities (as per protocol-defined 
acceptable ranges), and protocol-defined abnormal electrocardio gram results at screening 
3. All women must have a negative serum pregnancy test at screenin g and one day prior to 
challenge.  
4. Agreement by participants to use an adequate method of contrace ption§ during the study 
and for 4 weeks before and after the challenge. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 24 of 69 
 5. Able to pass a written examination (comprehension assessment te st) with a score of ≥70%, 
in order to demonstrate their comprehension of this study. If a  participant scores at least 
50%, then they will be given one more opportunity to re-test af ter further re-education. 
6. Willing and able to comply with the study requirements and proc edures. 
§ Adequate contraception is defined as a contraceptive method w ith failure rate of less than 1% 
per year when used consistently and correctly and when applicab le, in accordance with the 
product label; includes, but is not limited to, barrier with ad ditional spermicidal foam or jelly, 
intrauterine device, hormonal contraception (started at least 4  weeks prior to study 
enrollment), or women who have intercourse limited to men who u nderwent vasectomy. 
6.2 Participant Exclusion Criteria 
1. Clinically significant history of immunodeficiency, cardiovascu lar disease, respiratory 
disease, endocrine disorder, liver disease, renal disease, gast rointestinal disease, anal or 
rectal disorders, neurologic disease,  
2. Current nicotine use or drug, alcohol abuse within the past 6 m onths 
3. Recipient of bone marrow or solid organ transplant 
4. Use of systemic chemotherapy in the past 5 years 
5. Has a malignancy (excluding localized non-melanoma skin cancers ) or lymphoproliferative 
disorders diagnosed or treated within the past 5 years 
6. Received or plans to receive systemic immunosuppressive therapy , radiation therapy, 
parenteral or high-dosage inhaled steroids (> 800 Pg/day of beclomethasone dipropionate 
or equivalent) within 6 months prior to the enrollment through 28 days after challenge 
7. Have a history of hospitalization for psychiatric illness, suic ide attempt, or confinement for 
danger to self or others, within the past 10 years. Participant s with a psychiatric disorder 
(not meeting exclusion criteria, e.g., attention-deficit hypera ctivity disorder) that is 
controlled for a minimum of 3 months and the investigator has d etermined that the 
participant’s mental status will not compromise the participant ’s ability to comply with 
protocol requirements may be enrolled 
8. Have an elevated blood pressure, systolic ≥150 mmHg or diastoli c ≥90 mmHg, before 
challenge 
9. Taking any of the drugs listed in Appendix F that are metaboliz ed by CYP2C9 or any of the 
following psychiatric medications: aripiprazole, carbamazepine,  chlorpromazine, 
chlorprothixene, clozapine, divalproex sodium, fluphenazine, ha loperidol, lithium carbonate, 
lithium citrate, loxapine, mesoridazine, molindone, olanzapine,  perphenazine, pimozide, 
quetiapine, risperidone, thioridazine, thiothixene, trifluopera zine, triflupromazine, or 
ziprasidone 
10. History of Guillain-Barré Syndrome  
11. Too low or too high a BMI (BMI < 18.5 or > 39) 
12. Has an abnormal stool pattern defined as fewer than 3 stools pe r week or more than 2 
stools per day within the past 6 months, and any loose stools ( grade 3 or higher) during the 
1–2 day acclimation period before challenge 
13. Has regularly used laxatives in the past 6 months 
14. Has a history of eating disorders (e.g. anorexia or bulimia) wi thin the past 10 years 
15. Known allergy or previous severe adverse effect to all of the f ollowing antibiotics:  
ciprofloxacin (or quinolones), azithromycin and doxycycline.  
16. Previously received a licensed or investigational cholera vacci ne, within 10 years 
17. History of cholera or enterotoxigenic Escherichia coli  (ETEC) infection (lab-confirmed natural 
infection or experimental challenge), within 10 years 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 25 of 69 
 18. Travel to a cholera-endemic area in the past 5 years 
19. Pregnant or nursing 
20. Positive serology for human immunodeficiency virus (HIV), hepat itis B antigen, or hepatitis C 
antibody 
21. Protocol-defined (appendix B) clinically abnormal 12-lead ECG a t screening in the judgment 
of the Investigator, or based on the formal 12-lead ECG reading  by a cardiologist; history of 
any cardiac abnormalities, including conduction abnormalities s uch as Wolff-Parkinson-
White, dysrhythmias, or coronary artery disease 
22. Presence of a clinically significant abnormality on physical ex amination, including (but not 
limited to): pathologic heart murmur, lymphadenopathy, hepatosp lenomegaly, large 
abdominal scar of unclear origin 
23. Has poor venous access, defined as the inability to obtain scre ening blood tests after three 
attempts 
24. Currently on, or plans to be on, antibiotics (e.g., doxycycline ) within 14 days prior to 
challenge and through 28 days after challenge 
25. Presence of an acute illness or fever (>100.4°F) within 72 hour s of admission to the inpatient 
Clinical Research Unit 
26. Taking any prescription or over-the-counter medications that co ntain aspirin, non-steroidal 
anti-inflammatory drugs (NSAIDs), antacids, proton pump inhibit ors (PPIs), anti-diarrheals, 
etc. within 72 hours prior to challenge 
27. Received an investigational product within 30 days prior to ran domization ( for the 
monoclonal antibodies- 90 days prior to randomization) or plann ing to participate in 
another research study involving investigational product during  the conduct of this study 
28. Participants must not have donated blood in 8 weeks prior to st udy entry and agreed to not 
donate blood during and for 4 weeks following their active part icipation in this study 
29. Lack of ability to fully understand the informed consent 
30. Any other condition(s) that in the opinion of the investigator would jeopardize the safety or 
rights of a participant participating in the trial or would ren der the participant unable to 
comply with the protocol 
 
6.3 Strategies for Recruitment and Retention 
 
Volunteers will be recruited from the greater Baltimore area.  They will be recruited using standard 
procedures for Pharmaron clinical trials. Volunteers for inpati ent challenge studies are carefully 
screened on the details of the protocol, their time commitment,  and the nature of the confinement 
on a quarantine ward. At the end of screening volunteers will t ake a test to make sure that they 
understand the study.  They are also screened for general healt h.  Volunteers receive a stipend for 
each visit and day in confinement that has been approved by the  Advarra IRB.  
 
6.4  Withdrawal from Study 
6.4.1 Reasons for Withdrawal or Termination 
Participation in the study is strictly voluntary.  Participants  have the right to withdraw from the 
study at any time and for any reason, without penalty.   
The Principal Investigator (PI) and/or designee may withdraw a participant from continuing in the 
study for the following reasons: 
• Pregnancy 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 26 of 69 
 • Significant study intervention non-compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study  would not be in the best 
interest of the participant 
• Disease progression which requires discontinuation of the study  intervention 
• If the participant meets an exclusion criterion (either newly d eveloped or not previously 
recognized) that precludes further study participation 
• It is considered to be in the participant’s best interest, or i f the participant is not willing or 
able to comply with the study requirements.   
6.4.2 Handling of Participant Withdrawals or Termination 
Every effort will be made to undertake protocol-specified safet y follow-up procedures to capture 
AEs, serious adverse events (SAEs), and unanticipated problems (UPs). In the event of withdrawal 
from study, reasonable efforts should be made to conduct the fo llowing procedures: 
x Update any ongoing AE/SAEs that remain ongoing at time of parti cipant’s last visit prior to 
withdrawal  
x Query about AEs, SAEs and concomitant medications if the interv al between the 
participant’s last visit and the time of withdrawal is within t he protocol defined reporting 
period 
x Physical examination 
x Blood for safety laboratory testing if withdrawal occurs before  Visit 2 
x Update contact information 
The reason for participant discontinuation or withdrawal from t he study will be recorded on the 
Case Report Form (CRF). Participants who sign the informed cons ent form and are randomized but 
do not receive the challenge may be replaced.  Participants who  sign the informed consent form, 
and are randomized and receive the challenge, and subsequently withdraw, or are withdrawn or 
discontinued from the study, will not be replaced. 
 
6.5 Premature Termination or Suspension of Study  
Although the study Sponsor has every intention of completing th is study, it may be temporarily 
suspended or prematurely terminated if there is sufficient reas onable cause. The Sponsor reserves 
the right to terminate the study at any time for clinical or ad ministrative reasons. Written 
notification, documenting the reason for study suspension or te rmination, will be provided by the 
suspending or terminating party to PI and the FDA. If the study  is prematurely terminated or 
suspended, the PI and/or designee will promptly inform the IRB and will provide the reason(s) for 
the termination or suspension.  
Circumstances that may warrant termination or suspension includ e, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stopping  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
Study may resume once concerns about safety, protocol complianc e, data quality are addressed and 
satisfy the sponsor, IRB and/or FDA. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 27 of 69 
 7 STUDY AGENTS 
 
7.1 Study Agent and Control Description  
7.1.1 Product Description 
The iOWH032 drug product is a chemically and physically stable immediate-release oral tablet.  The 
key characteristics of iOWH032 tablets include fast disintegrat ion time (less than five minutes), 
similar to micro-suspension (which was used for phase 1 SAD and  MAD studies), and good chemical 
and physical stability under long-term storage conditions. The placebo will be matched in terms of 
visual appearance, disintegration time, and taste. 
7.1.2 Manufacturer   
The iOWH032 drug substance for this study was manufactured by A lbany Molecular Research, Inc., 
Albany, New York, United States (Batch Number 6798).   The iOWH032 drug product and placebo for this study will be man ufactured by Syngene 
International Ltd., Bengaluru, India (Batch Number TBD) 
7.1.3 Acquisition 
iOWH032 drug product and placebo will be shipped to the site fr om Syngene International Ltd., 
Bengaluru, India.   
7.1.4 Formulation, Appearance, Packaging, and Labeling   
Each 250 mg iOWH032 tablet contains 40% of iOWH032 (w/w) and 60 % excipients (w/w) including 
Mannitol 60®, Avicel® PH-101, Kollion CL-F®, Kollidon30®, Aeros il® 200 Pharma, and magnesium 
stearate. The matching placebo is made of the same excipients, but without the active drug 
substance.  Uncoated iOWH032 tablets and matching placebos have a white, ci rcular, biconvex appearance and 
their manufacturing process involves blending, wet granulation,  drying, milling, and tableting. 
 All packaging and labeling operations will be performed accordi ng to current Good Manufacturing 
Practices (cGMPs) and Good Clinical Practices (GCPs) and local requirements.   
 
All drug packages should be inspected on receipt at the study s ite for signs of damage. Evidence of 
damaged study drug is to be reported to the sponsor and stored under the labeled conditions until 
further instructions have been provided.
 
7.1.5 Product Storage and Stability 
The study drugs must be kept in a securely locked, substantiall y constructed enclosure to which 
access is limited (e.g., locked cabinet). The investigator will  take adequate precautions, including 
locked storage, to prevent theft or diversion of the study drug , consistent with International Council 
on Harmonisation-Good Clinical Practice (ICH-GCP). Within the l ocked storage area, study drug will 
be stored in accordance with the conditions specified on the dr ug labels (i.e. stored in tightly closed 
bottles at or below 30 °C without direct exposure to sunlight) until used.  
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 28 of 69 
 On receipt of the study drug, the investigator or designee will  perform an inventory of the shipment, 
comparing the shipment inventory to study drug actually receive d, and complete and sign an 
inventory log. The investigator or designee must count and veri fy that the shipment contains all of 
the items appearing on the shipment inventory. The investigator  must immediately notify PATH or 
the drug distribution contractor of any damaged or unusable stu dy drug that the site receives, and 
document any damaged or unusable study drug in the inventory lo g.  
 The investigator or designee will retain a copy of the shipment  inventory received with the drug 
supply in the study file, send a copy to the PATH-designated re presentative, and forward the original 
to the drug distribution center. 
 
 
Previous lots of iOWH032 have demonstrated good physical and ch emical stability under a variety of 
storage conditions (25°C/60% RH, 30°C/75% RH, 40°C/75% RH) in s tudies lasting 18 months. The 
current lot will be under stability for 18 months at 25°C/60% R H. 
7.1.6 Preparation 
Dose preparation, as described in detail in the Pharmacy Manual , will be carried out by a qualified 
unblinded research pharmacist.  
7.1.7 Dosing and Administration   
All participants will receive 500 mg iOWH032 (two 250 mg tablet s) or matching placebo three times 
a day  with meals, approximately 8 hours part, for 3 consecutive days according to randomized 
treatment assignment. The treatment will begin at the onset of diarrhea symptoms (first Grade 3 or 
over stool) or 48 hours after challenge, whichever is sooner.  
7.1.8 Route of Administration  
iOWH032 and placebo tablets will be administered orally.   
7.1.9 Starting Dose 
All doses are set at 500 mg (two 250 mg tablets) for iOWH032 or  two matching placebo tablets. 
7.1.10 Dose Adjustments/Modifications/Delays 
No dose adjustments are allowed.  A delay in dosing for safety reasons is allowed, in case of delayed 
dosing those participants will be removed from the pK populatio n.  PATH Medical Officer should be 
notified if the investigator delay s dosing due to safety reason s.  PATH Medical Officer, in 
collaboration with the investigator, will determine if dosing c an be reinitiated. The date and reason 
that dosing was delayed must be recorded in the source document ation and case report form, as 
applicable.  
7.1.11 Duration of Therapy 
Study drug will be administered three times a day, approximatel y 8 hours part, for 3 consecutive 
days.   
7.1.12 Tracking of Dose 
Each dosing will be directly observed by study staff. Appropria te staff will record each study drug 
administration (date and stop/start times) in the participant’s  chart (source document) and 
electronic case report form (eCRF).  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 29 of 69 
  
7.2  Challenge Strain Description 
7.2.1 Product Description 
Freshly-harvested, wild-type V. cholerae  El Tor Inaba strain N16961 will be the challenge agent. 
Strain N16961 will be delivered at 106 cfu, suspended in 30 mL of sodium bicarbonate solution 
(~1.3% NaHCO 3). 
7.2.2 Manufacturer   
Investigators at CVD developed the cholera challenge model usin g freshly harvested V. cholerae  El 
Tor Inaba strain N16961. For this study, CVD will develop the m aster cell bank to be administered to 
participants. 
7.2.3 Acquisition 
Freshly-harvested, wild-type V. cholerae  El Tor Inaba strain N16961 will be prepared by University of 
Maryland, Baltimore (UMB), Center for Vaccine Development (CVD) . Vials of strain N16961 are 
stored in the CVD Clinical Microbiology Lab at -70°C (-60°C or colder). 
7.2.4 Formulation, Appearance, Packaging, and Labeling   
Final containers hold 1 mL strain N16961 with ~109 cfu/mL in cryovials with gasketed screw-caps. 
The following information is contained on the label of each via l: “New Drug Limited by Federal (US) 
Law to Investigational Use”, Lot #xxx, Manufacture date xx/xxx/ xxxx.” 
7.2.5 Product Storage and Stability 
It is anticipated that the cell bank will be stable for years i f maintained frozen at -70°C (-60°C or 
colder). 
7.2.6 Preparation 
Two days before the challenge date, inoculum preparation will b egin from a WCB vial of frozen V. 
cholerae  strain N16961.The WCB strain will be plated onto Hy-Soy Agar p lates. After incubation at 
37°C overnight, one colony will be selected and will be plated onto Hy-Soy Agar plate and 
Thiosulfate-citrate-bile salts-sucrose agar plate (TCBS). After  incubation at 37°C overnight, colonies 
that exhibit characteristic Vibrio  appearance will be picked for heavy growth of organisms as wel l as 
for identity tests (morphology, Gram’s staining and agglutinati on with Vibrio antiserum). From the 
heavily seeded Hy-Soy Agar plates, growth will be harvested int o sterile phosphate buffered saline 
(PBS) . The bacterial suspension will be diluted with sterile PBS to p roduce a turbidity measured by 
optical density (OD) 660 nm to correspond to the desired bacter ial count of a target of 106 CFU/mL. 
The final stock dilution of challenge inoculum will be in a tub e labeled with:  organism identity, 
concentration, date, time, and “Caution: New Drug (limited to i nvestigational use)”. This tube will be 
kept at room temperature and transported to the Research Isolat ion Ward. Inoculum colony counts 
will be performed before and after challenge to document the fi nal concentration of inoculum.  
7.2.7 Dosing and Administration   
Fasting eligible participants will drink 120 mL of sodium bicar bonate solution (~1.3% NaHCO 3); 
approximately 1 minute later, participants will ingest 106 cfu of the challenge strain suspended in 30 
mL of sodium bicarbonate solution (~1.3% NaHCO 3).  Participants will have nothing by mouth, 
except water, for 90 minutes before or following ingestion of t he challenge inoculum. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 30 of 69 
 7.2.8 Route of Administration  
The challenge strain will be administered orally.  
7.2.9 Starting Dose 
The challenge dose is a single inoculum of 106 cfu of V. cholerae  El Tor Inaba strain N16961.  
7.2.10 Dose Adjustments/Modifications/Delays 
No dose adjustments are allowed. Challenge will not be re-admin istered if a subject who vomits the 
challenge dose shortly after dosing.  
7.2.11 Duration of Therapy 
The challenge inoculum will be administered in a single dose on ly. 
7.2.12 Tracking of Dose 
The challenge inoculum dosing will be directly observed by stud y staff. Appropriate staff will record 
each study drug administration (date and stop/start times) in t he participant’s chart (source 
document) and eCRF.  
7.3 Study Agents Accountability Procedures 
The site pharmacist will maintain complete records of all study  drug received from the Sponsor and 
will be responsible for maintaining an accurate record of the r andomization codes, inventory, and an 
accountability record of iOWH032, challenge material and placeb o for this study.  The site 
pharmacist will also be responsible for ensuring the security o f these documents.   At the end of the 
study, the site will receive instruction from the Sponsor regar ding the final disposition of any 
remaining study drug.   
8 STUDY PROCEDURES AND SCHEDULE 
 
8.1 Study Procedures/Evaluations 
8.1.1 Study Specific Procedures 
Study procedures and evaluations done as part of the study incl ude: 
x Medical history: a comprehensive medical history will be collec ted by interview with the 
participant including participation in clinical trials, surgery , previous hospitalization, allergy 
to food/drugs, and history of any chronic or recurrent medical conditions.  
x Interval medical history: inquiry regarding changes since the l ast medical history discussion 
including signs and symptoms. 
x Medication history from the past 4-weeks and current medication s taken, including 
prescription and over-the-counter medications. 
x Physical examination: full physical examination will include as sessment of vital signs, head, 
eyes, ears, nose, oropharynx, neck, chest (auscultation), lymph  nodes (neck, supraclavicular, 
axillary, inguinal), abdomen (auscultation and palpation), musc uloskeletal, skin, and 
neurological.   
x ECG and pregnancy testing 
x Safety Laboratory: Blood, stool, and urine specimens collected and evaluated 
x Blood sampling for study drug pK analysis 
x Cholera Challenge, iOWH032 and placebo administration and antib iotic treatment   
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 31 of 69 
 8.1.2 Standard of Care Study Procedures 
As all participants in this trial are healthy volunteers, there  are no standard of care procedures that 
would have been conducted if the individuals were not enrolled into the trial.  
 Standard of care procedures for the treatment of cholera includ e management of hydration levels, 
electrolyte balance, and also prescription with a course of ant imicrobials. Details of these 
procedures can be found in Section 9.   
8.2 Laboratory Procedures/Evaluations 
8.2.1 Clinical Laboratory Evaluations 
Protocol-mandated clinical screening and safety laboratory test s will be conducted in real time by 
laboratories that are properly accredited. These tests include:  
x Biochemistry: Sodium, Potassium, creatinine,  alkaline Phosphatase, total bilirubin, alanine 
aminotransferase (ALT), albumin, aspartate aminotransferase (AS T), Creatinine 
Phosphokinase (CPK), Glucose 
x Hematology: hemoglobin, white blood cells with differential cou nt, platelet count 
x Serology: HbSAg, anti-HCV, and HIV 
x Blood typing 
x Pregnancy test: Serum β-HCG 
Screening labs may be repeated once if certain values are outsi de the acceptable ranges and if the 
value does not increase the risk to the subject in the opinion of the clinical investigator.  If a subject 
with repeated Grade 1 abnormal lab values judged not clinically  significant by the PI, with the 
concurrence of the Sponsor’s Medical Officer, she/he will remai n eligible for enrollment into the 
study.   Additional blood specimens (2 mL) will be collected for iOWH032  pK analysis Day 1 and Day 3 of the 
study.   
8.2.2 Stool Specimen Preparation, Handling, and Storage 
Stool Culture: All loose stools will be collected, graded, and weighed while volunteers are in the 
Clinical Research Unit. Quantitative cultures will be performed  on the first two stool samples of each 
24-hour period prior to the initiation of antibiotics. Stool sp ecimens will be inoculated onto 
thiosulfate citrate bile salts sucrose (TCBS) agar plates eithe r directly or after overnight incubation 
enrichment in alkaline peptone water before plating onto TCBS a gar. Up to 2 stools daily will be 
cultured to determine the number of organisms per gram of stool . A rectal swab will be obtained if 
no stool was passed. Suspicious colonies will be agglutinated w ith polyvalent anti-O1 antisera.6 
Subsequent to the initiation of antibiotics, one stool sample f or each 12-hour period (or a rectal 
swab if subject cannot produce stool) will be submitted for qua litative culture only. Three sequential 
negative stool cultures are required for discharge from the Cli nical Research Unit.  
8.2.3 Specimen Shipment 
All biological  specimens will be transported using packaging mandated by CFR 4 2 Part 72.  All 
dangerous goods materials, including diagnostic specimens and i nfectious substances, must be 
transported according to instructions detailed in the Internati onal Air Transport Association 
Dangerous Goods Regulations. Biohazardous waste will be contain ed according to institutional, 
transportation/carrier, and all other applicable regulations.   
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 32 of 69 
  
8.3 Study Schedule 
8.3.1 Screening (Outpatient Clinic Visit 1) 
Potential volunteers may be screened for eligibility up to 85 d ays prior to enrollment. Interested 
potential participants will be recruited through standard proce dures at Pharmaron and brought to 
the study site for screening and consenting. 
Pharmaron research staff will provide a detailed description of  all aspects of the study, including the 
rationale and background, the public health significance, the p rocedures and schedule of visits, and 
a detailed discussion of the risks and the presence or absence of benefit to them, as appropriate.  
After the informed consent form is signed, the participant is i nterviewed one-on-one by a member 
of the study team to discuss the study. A brief written examina tion is administered to assess the 
volunteer’s comprehension of the study (i.e., Comprehension Assessment Tool ). If this quiz is passed 
(≥70% correct answers), the research staff complete the medical  history and concomitant 
medication forms, draw blood for eligibility testing, and obtai n an electrocardiogram (ECG). The 
participant also meets the principal investigator, or designee,  and has a physical examination to 
complete the eligibility screening. If the participant has pass ed all the eligibility criteria, he/she is 
then invited to proceed in the study and is given an appointmen t for the next visit.  The screening 
procedures may be completed in a single day or on multiple days , as long as the screening 
procedure dates do not exceed 85 days prior to challenge. 
It is recognized that volunteer studies must be carried out in an environment where no coercion is 
applied, and where volunteers can be adequately informed of the  purpose, nature, procedures, risks 
and hazards of the study. To assess and document comprehension of the material presented, each 
participant must pass a written quiz (score 70% or higher) cont aining approximately 20 multiple 
choice and true/false questions covering all aspects of the stu dy including the purpose, procedures, 
risks, benefits and pertinent microbiology. Incorrect answers w ill be reviewed with the participant.   
If the participant scores at least 50% the quiz may be retaken once, after further education and a 
review of the consent form. The Comprehension Assessment Tool  is dated and signed by the 
participant and by a research staff member and made part of the  permanent record.  
Another important feature of the consent process is the repeate d demonstration of both initiative 
and reliability by the prospective participant. There are multi ple opportunities for the participant to 
decline to proceed further in the process. This deliberate educ ation and screening process 
contributes to the informed nature of the participant’s consent . The process also increases the 
likelihood that the participant will be committed to completing  the entire inpatient containment 
portion of this study. Prospective participants will be careful ly screened to ensure that they are in 
good physical and mental health. 
The screening procedures include:  
• Signed, witnessed informed consent • Administration of the study Comprehension Assessment Tool  • Obtain vital signs (oral temperature, blood pressure, pulse, height, and weight) 
• Collection of medical history • Collection of concomitant medication history • Perform physical examination, to be performed by a study PI o r designee 
• Perform 12-lead electrocardiogram (ECG); the interpretation o f screening ECG eligibility is 
defined in Appendix B . 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 33 of 69 
 • Obtain the following screening laboratory studies (~18 mL blo od); the acceptable values for 
the screening laboratory tests are defined in Appendix B : 
o Complete Blood Count (CBC) with differential and platelet cou nt for the evaluation of 
WBC, ANC, Hemoglobin, and Platelets 
o Sodium, Potassium, Creatinine, Albumin, AST (SGOT), ALT (SGPT ), Alkaline Phosphatase, 
and Total Bilirubin, CPK, Glucose 
o Blood Type (e.g., A, B, or O) o Urinalysis for the evaluation of glucose and protein o Pregnancy test (serum β-HCG) o HIV antibody o Hepatitis B surface antigen 
o Hepatitis C antibody 
Note: Since intravenous fluids is a part of the planned managem ent of severe diarrhea, if more than 
3 attempts at venipuncture are required for obtaining screening  labs, then we will consider that 
person ineligible on the basis of poor venous access. 
8.3.2 Inpatient Containment Period 
Study participants determined to be eligible will be scheduled for admission to the inpatient 
containment unit (Clinical Research Unit). The anticipated dura tion of the inpatient stay is 11 days, 
participant to completion of discharge criteria, described belo w. 
8.3.3 Acclimatization (1 day prior to challenge, Day -1) 
Study participants will start their inpatient stay 1 day prior to challenge for acclimatization, during 
which we educate and familiarize each participant with the prot ocol-required procedures (e.g., stool 
handling), hygiene practices, and the “Rules and Procedures” to  be followed while in the inpatient 
unit.  In addition, during the acclimatization period, we monit or behavior, person-to-person 
interactions, mood, etc. to assess each study participant for a ny behavior or attitudes, which might 
not be appropriate for an inpatient containment study (i.e., co mbativeness, anti-social behavior, 
anger outbursts, destruction of property, etc.).  Any evidence that a participant may demonstrate 
which might pose a safety risk to themselves, other participant s, or staff could be cause for 
ineligibility for challenge and the remainder of the inpatient stay. Refusal to comply with protocol-
required procedures, adherence to hygiene practices, or repetit ive breaking of the “Rules and 
Procedures” could also constitute ineligibility.  This observat ion during the acclimatization period 
may be considered an imperfect and rather subjective method, bu t we have not identified any other 
good alternate objective measures that substitute for this dire ct observation procedure.  Any 
participant who is deemed ineligible will be discharged, prior to challenge.  
Baseline Clinical Safety Laboratory (~10 mL) will be obtained p rior to challenge to include: 
x Complete Blood Count (CBC) with differential and platelet count  for the evaluation of WBC, 
ANC, Hemoglobin, and Platelets 
x Sodium, Potassium, Creatinine, AST (SGOT), ALT (SGPT), Albumin,  Alkaline Phosphatase, and 
Total Bilirubin, CPK, Glucose 
A serum pregnancy test (must be negative) will be performed for  all women.  A pre-challenge stool 
sample will be collected as a baseline, however if a subject fa ils to produce a screening stool sample 
it will not be considered a protocol deviation. 
All participants that continue to demonstrate eligibility and p rovide continuing consent will fast 
(defined by nothing by mouth except for water) for 90 minutes b efore ingestion of the challenge 
inoculum. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 34 of 69 
 8.3.4 Challenge Day (Day 1) 
On the morning of challenge, fasting participants will have bas eline vitals (oral temperature, pulse, 
and blood pressure) recorded and a final eligibility confirmati on will be completed prior to oral 
ingestion of the challenge inoculum.   
Fasting eligible participants will drink 120 mL of sodium bicar bonate solution (~1.3% NaHCO 3); 
approximately 1 minute later, participants will ingest 106 cfu of the challenge strain suspended in 30 
mL of sodium bicarbonate solution (~1.3% NaHCO 3).  Participants will have nothing by mouth, 
except water, for 90 minutes before and following ingestion of the challenge inoculum. 
All back-up study participants that are not challenged will be discharged from the inpatient ward 
upon the completion of the target number of challenges.  Blinde d randomization will occur for all 
participants that successfully complete the ingestion of challe nge.  
8.3.5 Post-Challenge Observation Period (Day 1 through discharg e) 
At the onset of symptoms or by 48 hours after ingesting challen ge inoculum of 106 cfu of V. cholerae  
El Tor Inaba strain N16961, blinded study drug will be administ ered for 3 days every 8 hours to all 
study participants. After each dose of blinded study drug, the following tolerability will be assessed: 
nausea, abdominal discomfort and pain, occurrence of abdominal cramps, occurrence of headache, 
and occurrence of malaise, anorexia, pollakiuria,  micturition urgency, sinus tachycardia, increased 
alertness ; an attribution must be determined as related to stu dy drug, cholera, or an alternate 
etiology (unrelated to study). 
Following ingestion of the challenge inoculum, the following pr ocedures will be performed: 
• All stools will be graded for consistency (Grade 1-5) and any  diarrheal stool (Grade 3 or 
higher) will be weighed.  We assume a 1:1 weight per volume con version for diarrheal stools.  
• Any vomitus will also be collected and weighed.   
• Vital signs will be measured at least 3 times daily (approxim ately every 8 hours). On Day 1 
including the pre-challenge vitals assessment, there will be 4 vital signs assessments (1x pre-
challenge and 3x post-challenge). Vital signs will also be meas ured every 4 hours when a 
participant has a fever ≥ 39˚C (102.1˚F) and diarrhea, until th e participant has 2 consecutive 
temperatures of ≤ 38˚C (100.4˚F) and cessation of diarrhea. (Se e Section 9 for detailed 
procedures for the management of illness) 
• During the first 7 days following challenge, the highest grad e of an adverse symptom over 
that day will be assessed.  The documentation of the previous d ay’s highest grade of an 
adverse symptom (prior 24 hours) will include an attribution: s tudy drug, cholera, or an 
alternate etiology (unrelated to study). The anticipated subjec tive adverse symptoms include 
abdominal discomfort and pain, nausea, abdominal cramps, malais e, headache, and 
anorexia. These adverse symptoms will be graded according to th e scales shown in Appendix 
E. 
• For each of the first 7 days, the maximum temperature, total diarrheal stool volume, number 
of diarrheal stools, total vomitus volume, and number of vomiti ng episodes will be 
calculated. 
x Serum samples will be collected 7±1 hour after the first and th e last dose of the iOWH032 for 
pK analysis 
The management of clinical illness is described in Section 9.0 and Manual of Operating Procedures 
(MOP); including: criteria for oral and/or intravenous rehydrat ion, necessity of increased frequency 
of vital signs monitoring, unscheduled physical examinations, o btaining clinical safety labs, and the 
initiation of antibiotic or anti-pyretic therapy. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 35 of 69 
 8.3.6 Discharge Criteria 
Participants will not be allowed to leave the Clinical Research  Unit until they demonstrate that they 
are no longer infectious and cannot present a hazard to the com munity. Therefore, each participant 
must meet all the following criteria to be discharged: 
• The participant has at least three negative sequential stool cultures (separated by ~12 hours 
apart each) from which V. cholerae  does not grow 
• The absence of moderate or higher grade objective reactogenic ity (diarrhea, fever, and 
vomiting) for at least 12 hours prior to discharge 
• The participant has completed a 3-day course of antibiotic th erapy, which may include  
o Ciprofloxacin 500 mg, twice daily 
o Azithromycin 500 mg, once daily (for those persons who are alle rgic to 
fluoroquinolones) 
o Doxycycline 300 mg, once daily (for those persons who are aller gic to 
fluoroquinolones) 
8.3.7 Early Termination/Early Discharge 
Participants that desire to withdraw from the study or are with drawn by the PI (e.g., due to 
continuing non-compliance or safety concerns) during the inpati ent period will be given instructions 
on appropriate follow up. If a participant desires to leave the  inpatient containment unit early, we 
will need to ensure that the participant is not infectious to t he community.  Therefore, we plan to 
administer either Ciprofloxacin 1000 mg or Azithromycin 1000 mg , as a directly observed oral dose 
prior to discharge—selection of antimicrobial will be based on potential allergies to medications and 
the subject must have a negative stool culture before being all owed to leave.  We will provide 
medication and give instructions for 2 additional days of the r espective antimicrobial, for self-
administration.  A document of early termination/withdrawal wil l be completed by the study staff 
and co-signed by the participant.  The participant will not be compensated for any inpatient days 
that are not completed, including the day of early termination.  
8.4 Outpatient Clinic Visit 2 (Day 15 ±1) 
Participants will be scheduled for an outpatient visit shortly after discharge, approximately 2 weeks 
after challenge. During this visit we will assess the emergence  of adverse events and for any changes 
to medical history and concomitant medications. 10 mL blood wil l be drawn for safety labs. 
8.5 Outpatient Clinic Visit 3 (Day 29 ±2) 
Participants will be scheduled for an outpatient visit approxim ately 4 weeks after challenge. During 
this visit we will assess the emergence of adverse events and f or any changes to medical history and 
concomitant medications. This is the last clinic visit schedule d. 
8.6 Final Follow-up – Visit 4 (Day 180 ±14) 
A final follow up visit will be completed by phone.  This visit  will only be for the collection of serious 
adverse events. 
8.7 Unscheduled Visit(s) 
Participants that experience any serious or severe adverse effe cts or experience an event of concern 
can be scheduled for an outpatient visit to have further evalua tion. If an unscheduled visit occurs, a 
member of the clinical study team (PI, sub-investigator, nurse coordinator, or clinical nurse) will 
interview and evaluate the participant to determine the cause o f the visit and provide care as 
needed. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 36 of 69 
 8.8 Concomitant Medications, Treatments, and Procedures 
Drugs used during the study will be reported in the Concomitant  Medication CRF, including both 
prescription, non-prescription, and over-the-counter medication . 
 
8.9 Prohibited Medications, Treatments, and Procedures 
Treatment with drug listed in Appendix F and antimicrobial agen ts other than the ones that will be 
used for the treatment of Cholera diarrhea will not be permitte d during the inpatient period unless 
discussed and approved by the PATH Medical Officer and PI. 
9 MANAGEMENT OF EXPECTED CHOLERA ILLNESS 
9.1 Clinical Evaluation 
Subsequent to cholera challenge, participants will remain on th e ward for approximately 10-11 days.  
Vital signs and oral temperature will be measured at least ever y 8 ±1 hours by staff nurses who 
remain on the ward 24h a day. Participants will be interviewed daily by a study physician to 
determine the occurrence of illness signs and symptoms (e.g., a norexia, malaise, abdominal cramps, 
and headache) which occurred during the previous study day; the se data will be recorded on a 
standardized form and graded in severity according to Appendix E.  A focused physical examination 
may be performed at the discretion of the physician according t o the nature of a participant’s 
complaint. 
9.2 Measurement of Diarrhea and Vomitus 
Since diarrhea is anticipated to be a common occurrence, all pa rticipants will be expected to collect 
every stool that is passed, from the time of challenge until di scharge.  Participants will be instructed 
to use a plastic stool collection basin, commonly called a “hat ”.  All stools will be graded by the study 
staff.  The grading of stool is based on consistency and the de finition of diarrhea is a grade 3 or 
higher stool, as follows: 
x Grade 1 – well formed (normal stool, does not take the shape of  the container) 
x Grade 2 – soft (normal stool, does not take the shape of the co ntainer) 
x Grade 3 – thick liquid (diarrhea, takes the shape of the contai ner readily) 
x Grade 4 – opaque watery diarrhea 
x Grade 5 – rice water diarrhea (clear watery) 
Any Grade 3 or higher stool (diarrheal stool) must be weighed, to estimate the volume of fluid loss 
(assume ~1 g diarrheal stool = 1 mL of fluid lost).   
Similarly, any episodes of vomiting should be collected in eith er a stool “hat” or a plastic “kidney” 
basin, provided.  If a vomiting or diarrhea episode is not able  to be collected in a basin (e.g., the 
participant has an “accident” while sleeping or before they are  able to reach a toilet), then the 
volume of the output will be estimated. 
9.3 Management of Fluid Loss 
Oral Rehydration Solution (ORS) will be offered as the primary means of management of fluid loss.  
Participants who develop diarrheal stools (Grade 3 or higher) d uring the inpatient observation will 
be required to ingest standard WHO Oral Rehydration Solution (O RS) at 1.5 times the stool volume. 
Vomitus will be replaced with ORS in equal amounts, 1:1 ratio. At the discretion of the investigator, 
additional ORS may be administered. ORS will be prepared accord ing to the manufacturer’s package 
insert (Jianas Bros ORS).  Unused ORS should be discarded 24 ho urs after preparation. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 37 of 69 
 For the duration of diarrhea, the participant will be requested  to provide a urine specimen from 
every void that they experience; the specimen will be tested fo r urine specific gravity.  In the event 
that intravenous fluids are required, serum electrolytes (Sodiu m, Potassium, Chloride, Bicarbonate), 
BUN, and creatinine will be measured.   
A physician is available by telephone or beeper at all times. N urses will notify the on-call physician if 
any of the following occurs in a participant who is experiencin g diarrhea and/or vomiting: 
x Syncope 
x Complaint of dizziness or lightheadedness or established orthos tatic hypotension 
x Urine specific gravity > 1.025 
x > 500 mL behind in ORS replacement 
x Vomiting of ≥ 500 mL once or total volume within the past 4 hou rs 
x High fever ≥ 39 qC (102.1qF) 
x Severe headache, severe malaise, or severe abdominal pain 
x Participant has a complaint for which he/she requests treatment  
x Any other clinical situation that concerns the nurse 
 
If a participant develops severe watery diarrhea or persistent vomiting and cannot maintain full 
hydration by oral means, according to the criteria on section 9 .5, IV fluid replacement will be 
administered.   
9.4 Frequency of Vital Signs Assessment 
Vital signs (blood pressure, pulse, and oral temperature) will be measured approximately every 8±1 
hours, unless more frequent monitoring is needed. Once a partic ipant has passed a diarrheal stool 
(Grade 3 or higher), vital signs will be measured every 4 hours  until the participant passes a Grade 1 
or 2 stool or 24 hours have passed since the last Grade 3 – 5 s tool, whichever comes first.   
Vital signs will also be measured every 4 hours when a particip ant has a fever ≥ 39 qC (102.1qF), until 
the participant has 2 consecutive temperatures of ≤ 38 qC (100.4qF).  
Any participant that complains of dizziness or lightheadedness upon standing will have orthostatic 
blood pressures assessed—BP after supine for ~5 minutes and BP after standing ~2-3 minutes. 
Orthostatic hypotension is defined as a drop in systolic BP > 2 0 mmHg or in diastolic BP > 10 mmHg. 
9.5 Fluid Therapy/Hydration 
Intravenous fluids (Lactated Ringers solution) will be administ ered to participants with diarrhea who 
meet any of the following criteria: 
x Orthostatic hypotension 
x Urine specific gravity > 1.025 
x No urine output for ≥ 8 hours 
x > 1000 mL deficit in ORS replacement 
x At the investigator’s discretion, based on clinical evaluation or on a participant’s difficulty in 
keeping up with ongoing diarrheal losses by oral rehydration al one 
Intravenous therapy will continue until the above criteria are no longer satisfied, the participant is 
able to take fluid by mouth, and a study physician determines t hat it is no longer required. 
9.6 Indications for Antibiotics 
Antimicrobials will be administered immediately if a participan t meets the criteria for severe cholera 
diarrhea, defined as ≥5 L (5 kg) of cumulative diarrheal stool.   All other participants who have not 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 38 of 69 
 met the criteria for severe cholera diarrhea will receive antib iotics at approximately 4 days after the 
challenge. Antimicrobials will continue for the completion of a  3-day course. In rare and unexpected 
instances, the study investigator will be allowed to administer  antimicrobials for alternate reasons—
e.g., if in his/her judgment it is necessary to ensure the safe ty of the participant.  
The administration of a defined course of antibiotics (which st arts, at the latest, on the fourth day 
post-challenge) results in the rapid elimination of susceptible  cholera organisms from the stool, such 
that it is extremely unlikely that the discharge criterion (for  three sequential negative stool cultures, 
~12 hours apart) will fail to be achieved by the tenth day post -challenge.  
If cholera organisms continue to be grown from stool cultures a fter the completion of the 3-day 
course of antibiotics, then another course of antibiotics can b e entertained.  Study participants will 
continue to be required to reside in the Clinical Research Unit  until all the discharge criteria are met.  
Participants will be compensated for the additional days on the  Clinical Research Unit.  This event is 
considered to be a very rare likelihood since failure to eradic ate the cholera challenge strain never 
occurred during nearly 40 years of experience using the N16961 strain. 
9.7 Indications for Other Concomitant Medications 
Any concomitant medication, prescription or over-the-counter, w ill be evaluated for continuation 
during the inpatient setting.  Any such medication will need to  be discussed with and approved by 
the investigator prior t o admission.  The supply of such medica tion will be the responsibility of the 
participant and will be handed over to the research staff upon admission; daily administration will 
be recorded.  Any un-declared prescription or over-the-counter medications that are discovered 
during the inpatient stay will constitute a violation of the wa rd “Rules and Procedures.”  
Other medications may be administered during the study period a s follows: 
x Smoking is not allowed on the ward, but participants will be ab le to request a nicotine 
patch.  
x An anti-pyretic and analgesic (i.e. acetaminophen) may be presc ribed for severe headaches, 
other pains, or fevers (e.g., sustained temperatures of ≥ 39 qC).   
x At the investigator’s discretion (e.g., upon review of serum el ectrolyte results during severe 
diarrhea), oral potassium may be administered for repletion of electrolyte losses. 
x Other medications, which are deemed necessary for the safety an d welfare of the 
participant  
The prescription of any medication must be ordered and signed b y the investigator and each 
administration recorded. 
10 ASSESSMENT OF SAFETY 
The assessment of the safety of the study drug and challenge ag ent will be through the detection 
and documentation of adverse effects, both solicited adverse ev ents (AEs) and unsolicited AEs, 
and/or clinically significant laboratory abnormalities, through  28 days post-challenge. Only the 
occurrence of serious adverse events (SAEs) will be reported be tween 28 days and 180 days post-
challenge. 
10.1 Specification of Safety Parameters 
10.1.1 Definition of Adverse Event (AE) 
An adverse event is any untoward medical occurrence in a partic ipant after administration of the 
investigational products and that does not necessarily have a c ausal relationship with the 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 39 of 69 
 investigational products.  An AE can therefore be any unfavorab le and unintended sign (including 
abnormal laboratory findings), symptoms, physical examinations,  or disease temporally associated 
with the use of the investigational products, whether or not re lated to the investigational products.  
This definition includes exacerbations of pre-existing conditio ns.  Stable pre-existing conditions 
which do not change in nature or severity during the study are not considered AEs; however, these 
should be reported as part of the medical history.  In certain instances, it may be not be possible to 
distinguish between relatedness due to study drug or cholera; i n those cases an AE may be noted as 
related to both. 
Any AEs that are reported after signing the study ICF up to the  Day -1 inpatient ward admission will 
be reported as a part of the medical history. 
Solicited AEs  are pre-specified AEs that could potentially be in association  with the study drug or 
cholera infection. Investigators will attempt to assign causali ty of solicited AEs to either the study 
drug, cholera infection, or an alternate etiology. A solicited AE is a predetermined event, identified 
in the Investigator’s Brochure, which may reflect safety concer ns related to the investigational 
product. 
Unsolicited AEs  are any AEs reported spontaneously by the participant, observe d by the study 
personnel during study visits or those identified during review  of medical records or source 
documents. Investigators will attempt to assign causality of un solicited AEs to either the study drug, 
cholera infection, or an alternate etiology. 
10.1.2 Definition of Serious Adverse Event (SAE) 
A serious adverse event (SAE) is any adverse event that results  in any of the following outcomes: 
1. Death 
2. A life-threatening event. Life-threatening events mean that the study participant was, in 
the opinion of the site PI or Sponsor, at risk of death at the time of the event; it does not 
refer to an event which hypothetically might have caused death if it were more severe.  
3. Requires inpatient hospitalization or prolongation of existi ng hospitalization  
4. Results in persistent or significant incapacity or substanti al disruption of the ability to 
conduct normal life functions  
5. Congenital abnormality or birth defect 6. Important medical event that may not result in one of the ab ove outcomes but may 
jeopardize the health of the study participant and/or requires medical or surgical 
intervention to prevent one of the outcomes listed in the above  definition of serious 
adverse event. Examples of such medical events include allergic  bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dysc rasias or convulsions 
that do not result in inpatient hospitalization, or the develop ment of drug dependency 
or drug abuse.  
All SAEs will be: 
• recorded in the research record  • reported to the local IRB, per local IRB guidelines • reviewed and evaluated by a study clinician, the PI and Indep endent Medical Monitor  
• followed through resolution by a study clinician 
All SAEs, whether related or unrelated, will be reported to the  PATH medical officer within 24 hours 
of site awareness. 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 40 of 69 
 10.1.3 Definition of Unanticipated Problems (UP) 
The Office of Human Research Protections (OHRP) considers unant icipated problems involving risks 
to participants or others to include, any incident, experience,  or outcome that meets all of the 
following criteria: 
x Unexpected in terms of nature, severity, or frequency given (a)  the research procedures that 
are described in the protocol-related documents, such as the IR B-approved research 
protocol and informed consent document; and (b) the characteris tics of the participant 
population being studied; 
x Related or possibly related to participation in the research (“ possibly related” means there is 
a reasonable possibility that the incident, experience, or outc ome may have been caused by 
the procedures involved in the research); and 
x Suggests that the research places participants or others at a g reater risk of harm (including 
physical, psychological, economic, or social harm) than was pre viously known or recognized. 
 This study will use the OHRP definition of UP.  
10.2  Classification of an Adverse Event 
10.2.1 Severity of Event 
Severity of Adverse Events :  All AEs will be assessed by the clinician using a protocol-d efined grading 
system in Appendix E.  For events not included in the protocol- defined grading system, the following 
guidelines will be used to quantify severity:  
Mild:  events require minimal or no treatment and do not interf ere with the participant’s 
daily activities. 
Moderate:  events result in a low level of inconvenience or con cern with the therapeutic 
measures. Moderate events may cause some interference with func tioning. 
Severe:  events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually incapacit ating. 
Life threatening:  any adverse drug experience that places the participant, in the view of the 
investigator, at immediate risk of death from the reaction as i t occurred, i.e., it does 
not include a reaction that had it occurred in a more severe fo rm, might have caused 
death. 
Changes in the severity of an AE should be documented to allow an assessment of the duration of 
the event at each level of intensity to be performed.  Adverse events characterized as intermittent 
require documentation of onset and duration of each episode. 
10.2.2 Relationship to Study Agent or Cholera Infection 
Relationship (causality or attribution) of all AEs to the study  drug, known cholera infection, or to an 
alternate etiology (unrelated to the study) is part of the docu mentation process, but it is not a factor 
in determining what is (or is not) reported in the study.  If t here is any doubt as to whether a clinical 
observation is an AE, the event should be reported.  
The PI must assign a relationship of each AE to the receipt of the investigational product. The 
investigator will use clinical judgment in conjunction with the  assessment of a plausible biologic 
mechanism, a temporal relationship between the onset of the eve nt in relation to receipt of the 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 41 of 69 
 investigational product, and identification of possible alterna te etiologies including underlying 
disease, concurrent illness, or concomitant medications. 
All AEs must have their relationship assessed using one of thre e terms:  related to study drug, 
related to cholera, or not related (an alternate etiology can b e identified and is likely or feasible).  To 
help assess, the following guidelines are used. 
Related to study drug (i.e., iOWH032 or placebo) – There is a r easonable possibility (perhaps 
due to the timing of onset of the symptoms) that the study drug  caused the adverse 
event. Reasonable possibility means that there is evidence to s uggest a causal 
relationship between the study drug and the adverse event.  
Related to cholera - There is a reasonable possibility that the  cholera infection caused the 
adverse event. Reasonable possibility means that there is evide nce to suggest a 
causal relationship between the cholera illness and the adverse  event. 
Not Related – There is not a reasonable possibility that the ev ent is related to either the 
study drug (i.e., iOWH032 or placebo) or cholera and there is a  reasonable alternate 
etiology. Thus, allergic reactions to the protocol-required ant imicrobial will be 
classified as “not related” and the alternate etiology will be designated as a reaction 
to the antimicrobial. 
10.2.3 Expectedness 
The study investigator will be responsible for determining whet her an AE is expected or unexpected. 
An AE will be considered unexpected if the nature, severity, or  frequency of the event is not 
consistent with the risk information previously described for t he study agent in the Investigator’s 
Brochure. 
 
10.3 Time Period and Frequency for Event Assessment and Follow- up 
The occurrence of an AE or SAE may come to the attention of stu dy personnel during study visits 
or upon review by a study monitor. All AEs including local and systemic reactions not meeting the 
criteria for SAEs will be captured on the appropriate CRF. Info rmation to be collected includes 
event description, time of onset, clinician’s assessment of sev erity, relationship to study product, 
and time of resolution/stabilization of the event. All AEs occu rring through 28 days post-
challenge, must be documented appropriately regardless of relat ionship. All AEs will be followed 
to adequate resolution.   Any medical condition that is present at the time that the part icipant is screened will be 
considered as baseline and not reported as an AE. However, if t he study participant’s condition 
deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the 
data collection system throughout the study.  
Changes in the severity of an AE will be documented to allow an  assessment of the duration of the 
event at each level of severity to be performed. AEs characteri zed as intermittent require 
documentation of onset and duration of each episode.  
The PI will record all reportable events with start dates occur ring any time after the challenge is 
obtained until 28 (for unsolicited AEs) or 180 days (for SAEs) after the last day of study participation. 
At each study visit, the investigator will inquire about the oc currence of AE/SAEs since the last visit. 
Events will be followed for outcome information until resolutio n or stabilization. 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 42 of 69 
 10.4  Reporting Procedures 
10.4.1 Adverse Event Reporting 
To improve the quality and precision of AE data, the investigat or should observe the following 
guidelines: 
• AEs must be graded, assessed for severity and causality, and reviewed by a site investigator. 
• Whenever possible, use recognized medical terms when reportin g AEs and avoid the use of 
colloquialisms or abbreviations. 
• If known, report the diagnosis (i.e., syndrome or disease) ra ther than component symptoms, 
signs or laboratory values (e.g., report congestive heart failu re rather than dyspnea, rales, and 
cyanosis); however, symptoms or signs that are considered unrel ated to an observed syndrome 
or disease should be reported as individual AEs (e.g., if conge stive heart failure and severe 
headache are observed at the same time, each event should be re corded as an individual AE). 
• AEs occurring secondary to other events (e.g., sequelae) shou ld be identified by the primary 
cause. A ‘primary’ AE, if clearly identifiable, generally repre sents the most accurate clinical term 
to report. For example: orthostatic hypotension → fainting and fall to floor → head trauma → 
neck pain; the primary AE is orthostatic hypotension, which is what should be reported. If a 
primary SAE is reported, events occurring secondary to the prim ary event should be described in 
the narrative description of the case. 
• Death is an outcome of an event. The event that resulted in t he death should be reported as 
the SAE. 
• For hospitalizations for surgical or diagnostic procedures, t he illness leading to the surgical 
or diagnostic procedure should be recorded as the SAE, not the procedure itself. The procedure 
should be captured in the case narrative as part of the action taken in response to the illness. 
• Elective surgical or diagnostic procedures with or without ho spitalizations (e.g., circumcision 
or elective abortion of a pregnancy) will not be recorded as an  AE. The procedure should be 
captured in the case narrative as part of medical history. 
10.4.2 Serious Adverse Event Reporting 
The study clinician will complete a SAE Form within the followi ng timelines:  
x All SAEs, whether related or unrelated, will be recorded on the  SAE Form and submitted to 
the PATH Medical Officer within 24 hours of site awareness. See  Section 1, Key Roles for 
contact information.  
 
Even if the investigator does not have complete information reg arding an SAE, the SAE should still 
be reported within 24 hours and once additional relevant inform ation is received, the report should 
be updated within 24 hours. The investigator should always prov ide an assessment of causality at 
the time of the initial report, even though this assessment may  subsequently change based on the 
follow-up information received. After receipt of the initial re port, PATH Medical Officer will contact 
the investigator if it is necessary to obtain further informati on for assessment of the event. 
 All SAEs will be followed until satisfactory resolution or unti l the site investigator deems the event to 
be chronic or the adherence to be stable. Other supporting docu mentation of the event may be 
requested by PATH and should be provided as soon as possible. P ATH will be responsible for 
notifying FDA of any unexpected fatal or life-threatening suspe cted adverse reaction as soon as 
possible but in no case later than 7 calendar days after the PA TH’s initial receipt of the information.
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 43 of 69 
 10.4.3 Unanticipated Problem Reporting 
Incidents or events that meet the OHRP criteria for UPs require  the creation and completion of 
an UP report form. It is the site investigator’s responsibility  to report UPs to Advarra and to 
PATH. The UP report will include the following information:  
x Protocol identifying information: protocol title and number, PI ’s name, and the Advarra 
Protocol number; 
x A detailed description of the event, incident, experience, or o utcome; 
x An explanation of the basis for determining that the event, inc ident, experience, or outcome 
represents an UP; 
x A description of any changes to the protocol or other correctiv e actions that have been 
taken or are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be re ported using the following timeline:  
x UPs that are SAEs will be reported to the IRB and to PATH withi n 24 hours of the investigator 
becoming aware of the event. 
x Any other UP will be reported to the IRB and to the study spons or within 72 hours of the 
investigator becoming aware of the problem. 
x All UPs should be reported to appropriate institutional officia ls (as required by an 
institution’s written reporting procedures), the supporting age ncy head (or designee), and 
OHRP within 96 hours of the IRB’s receipt of the report of the problem from the 
investigator. 
10.4.4 Reporting of Pregnancy 
iOWH032 has not been shown to be safe during pregnancy, so preg nant women may not participate 
in the study and women with child-bearing potential must agree to use effective methods of birth 
control 4 weeks prior to challenge and continue throughout the study. Although every effort will be 
made to counsel women about the pregnancy precautions related t o study participation, if a woman 
becomes pregnant during the treatment phase of the trial, effor ts will be made to obtain permission 
to continue to follow the participant through the pregnancy and  to document the outcome of the 
pregnancy. The pregnancy and its outcome will be documented, ev en if birth occurs after the 
scheduled end of the study for the participant.  A pregnancy in a participant is not in and of itself an 
AE. A pregnancy is reported as an AE or SAE only when there is suspicion that the investigational 
product may have interfered with the effectiveness of contracep tion or there was a serious 
complication in the pregnancy including a spontaneous abortion or an elective termination for 
medical rationale. The participant will be asked to provide ser ial follow-ups on the status of her 
pregnancy as well as provide health information on her infant f ollowing delivery. The participant will 
be asked to provide copies of clinic visits only if needed. The  participants will receive no further 
study drug but may continue to receive antimicrobials if needed . The participants will continue 
safety monitoring and all follow up visits as noted in the stud y schedule.  
 Principal investigator will notify study Independent Medical Mo nitor and PATH Medical Officer for 
participants that become pregnant during the study. Each pregna ncy must be reported immediately 
(within 24 hours of identification) by e-mail or fax to the spo nsor. 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 44 of 69 
 10.5 Study Halting Rules 
The study is planned to have each cohort of participants to be challenged at the same time. The 
greatest potential for risk is with the intentional cholera inf ection and with the dosing of the study 
drug (during the first 5 days post-challenge).  Should one of t he study halting criteria be met, all 
participants of that cohort (and the following cohort, if appli cable) will continue to be actively 
monitored and managed for their clinical illness (if during the  inpatient period) and continued to be 
followed for safety information (if during the outpatient perio d).  
If any of the following events occurs during the study, adminis tration of IP will be halted to all subjects 
in the study until a thorough joint review of the safety concer n is undertaken and completed by the 
Safety Review Committee (SRC) and PI. The halting rules refer t o suspected adverse reactions and will 
be triggered automatically if any of the events described below  are met during the conduct of the 
study: 
x One or more participants experience a serious adverse event rel ated to the study product.  
x Two or more participants experience the same severe (Grade 3) A E of the same organ class 
(systemic toxicity, or clinical laboratory tests or vital signs ) deemed related to the study 
product within seven days following the study drug administrati on 
x One serious and unexpected, solicited or unsolicited, suspected  or confirmed adverse 
reaction evaluated by the PI, Independent Medical Monitor, and PATH Medical Officer 
and determined to be an unacceptable risk to the health and saf ety of other 
investigational product recipients 
 
10.6 Safety Oversight 
Safety monitoring/oversight will be performed by a Safety Revie w Committee composed of three 
voting members (including two independent medical experts in th e field): a chair, co-chair,  and an 
independent medical monitor. The primary responsibility of the SRC is to monitor participant safety. 
The responsibilities of the SRC and safety oversight activities  are described in the protocol and will 
be clearly outlined in the SRC Charter. The SRC considers study -specific data as well as relevant 
background information about the disease, test article, and tar get population under study. The SRC 
will review challenge data shortly after completion of the inpa tient phase and will review the 
interim analysis after Cohort 1 has completed study activities  before proceeding to the second 
cohort.  One of the SRC members, a physician, will be a designa ted Independent Medical Monitor.  
The SRC will also be empowered to suspend the study, recommend amendments to the protocol, 
recommend proceeding with the next Cohort, and/or to request fu rther information for their 
Additionally, SRC will review the safety data only post enrollm ent of Cohort 2. 
The Independent Medical Monitor will be responsible for regular ly reviewing the cumulative safety 
data, including a review of safety laboratory test results and adverse event reporting, should there 
be a halt in the study or at the request of the SRC.  The SRC i s empowered with halting the study at 
any time. Should there be a halt in the study, no further chall enges or study drug dosing will be 
performed; all enrolled participants will continue to be follow ed; for participants that are in the 
Clinical Research Unit, the management of diarrhea or other sym ptoms will continue until 
resolution.  Antimicrobials will be administered immediately if a participan t meets the criteria for 
severe cholera diarrhea. Further drug administration, in accord ance with the protocol, may be 
resumed with the concurrence of the SRC, PATH Medical Officer a nd the PI. The sponsor will make 
the final determination as to whether the study will be stopped  permanently. If the study is 
permanently stopped, participants will be followed until their next scheduled study visit for the 
safety assessments or until AE/SAE resolution, whichever is lon ger. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 45 of 69 
 11 CLINICAL MONITORING 
Site monitoring is conducted to ensure that the rights and well -being of human participants are 
protected, that the reported trial data are accurate, complete,  and verifiable, and that the conduct 
of the trial is in compliance with the currently approved proto col/amendment(s), with GCP, and with 
applicable regulatory requirement(s). Monitoring refers to the methods used by sponsors of 
investigational studies, or Contract Research Organizations (CR Os) delegated site monitoring 
responsibilities, to oversee the conduct of, and reporting of d ata from, clinical investigations. Site 
monitoring includes ensuring appropriate clinical investigator supervision of study site staff and 
third party contractors.  
• Monitoring for this study will be performed by The Total Approa ch.  
• Monitoring visits will occur on-site throughout the study and w ill include 100% data 
verification of primary endpoint data (such as clinical signs a nd fluid output data) and 
excretion data. Targeted 10% data verification will be conducte d for vital signs and 
other non-critical data.    
• PATH Medical Officer will be provided copies of monitoring repo rts within 14 days of 
visit.  
• Details of clinical site monitoring are documented in a Clinica l Monitoring Plan. The 
Clinical Monitoring Pl an describes in det ail who will conduct t he monitoring, at what 
frequency monitoring will be done, at what level of detail moni toring will be performed, 
and the distribution of monitoring reports.  
• Independent internal audits will also be conducted, as describe d in the Pharmaron 
Quality Management Plan. The results of the internal audit are reviewed with the PI, 
coordinator, and Clinical Research Manager; Corrective Action P lans are formulated in 
response to any issue.   
12 STATISTICAL CONSIDERATIONS 
 
12.1 Statistical and Analytical Plans 
The statistical analysis will be conducted following the princi ples as specified in the International 
Conference on Harmonization (ICH) Topic E9 (ICH, 1998). The fin al statistical analyses will be 
performed after database lock and final unblinding of the data.  
 Full details of the statistical analysis and methods will be do cumented in a statistical analysis plan 
(SAP) which will be finalized prior the interim analysis.  The SAP will follow the general guidance of 
this protocol, and will further describe the selection of parti cipants to be included in the analyses, 
detailed statistical and analytical plans for both the interim and final analyses, and procedures for 
accounting for missing, unused, and spurious data.  
12.2 Statistical Hypotheses 
The null (H 0) and alternative (H 1) hypotheses of the primary efficacy endpoint analysis are as f ollows: 
H0:  The diarrheal stool output rate from participants treated wi th iOWH032 is not lower 
than that of participants treated with placebo. 
H1:  The diarrheal stool output rate from participants treated wi th iOWH032 is lower than 
that of participants treated with placebo. 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 46 of 69 
 The diarrheal stool output rate is defined as the total volume of diarrheal stools (mL, Grade 3 and 
above) divided by the number of hours between initiation of stu dy product dosing and initiation of 
antimicrobial therapy. The hypothesis is one-sided to permit th e interim analysis and clear description 
of efficacy/futility boundaries. See Section 12.5.8 for a descr iption of the one-sided alpha levels to be 
used for testing the primary endpoint. 
 This hypothesis test will be supp lemented with two-sided confid ence intervals for the difference of 
medians, as described below. Secondary efficacy endpoints regar ding AUC of diarrheal stool volume 
as well as quantitative culture of cholera organisms (defined b y AUC and peak shedding) from stool 
samples will be analysed with similar methods. 
 
The null (H
0) and alternative (H 1) hypotheses for the secondary analysis of the proportion of 
participants with moderate or severe diarrhea are as follows: 
H0:  iOWH032 and placebo do not differ in the proportion of parti cipants that develop 
moderate or severe diarrhea 
H1:  iOWH032 and placebo differ in the proportion of participants  that develop with 
moderate or severe diarrhea 
 
12.3 Timing of Analyses 
When all Cohort 1 participants have completed the inpatient con tainment period and primary 
efficacy endpoint data are available, an interim analysis of th e primary efficacy endpoint and 
accompanying safety data will be initiated. The study is design ed with binding efficacy and futility 
thresholds, described in Section 12.5.8. Cohort 2 will be enrol led following this interim analysis if 
neither overwhelming efficacy, nor evidence of futility is indi cated, with the final analysis resulting 
from the combined data from both cohorts. This process will inc lude the review of the safety data 
by the SRC and determination of lack of major safety signal.  
Additionally, topline results will be conducted on the after th e efficacy data data from Cohorts 1 and 
2 have been collected (i.e. including data prior to Visit 2).  These topline results will include analysis 
of the primary efficacy endpoint, as well as the analyses of th e secondary endpoints of proportion of 
participants with MSD, attack rate of any diarrhea, AUC of stoo l volume, duration of episode (time 
to first formed stool), and total number of loose stools conduc ted on the mITT population. In 
addition, subject disposition and demographic and baseline char acteristics tables will be provided. 
The topline results will be unblinded only to the treatment-lev el and not to the individual subject. To 
avoid identification of individual subjects, some summary stati stics such as minimum and maximum 
will not be presented in the summary tables.  The final statistical analyses will be performed after database  lock and final unblinding of the data.
 
12.4 Analysis Datasets 
Assignment of participants to analysis populations will be comp leted prior to unblinding, for each 
cohort.    For purposes of analysis, the following populations are defined : 
 
Population Description 
Enrolled  All participants who sign the ICF. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 47 of 69 
 Population Description 
Intent to Treat (ITT) All participants who are randomized to st udy treatment 
Participants will be analysed according to their randomized treatment. 
Modified ITT (mITT) The subset of ITT who receive at least one dose of study drug.  Any 
participant displaying no indication of cholera infection (no 
diarrheal stool output of grade 3 or higher) within 48 hours of  
challenge will be removed from the mITT population, prior to unblinding of data. 
Per Protocol Population The subset of the mITT consisting of th ose participants who had no 
major protocol deviations  and received all doses of assigned study 
drug.  
All protocol deviations will be assessed and documented on a 
case-by-case basis before the database lock, and deviations considered having a serious impact on the efficacy results will  lead 
to the relevant participant being excluded from the per-protoco l 
population. Before database lock, potential participant exclusi ons 
from per-protocol population will be reviewed by the Sponsor an d 
documented. 
Safety The Safety Analysis Set includes all participants who re ceived any 
study treatment. Safety analyses and demographic/baseline characteristic summaries will be based on the safety population , 
according to treatment received. 
 
12.5 Description of Statistical Methods 
12.5.1 General Approach 
This is a single-centre, double-blind, randomized, placebo-cont rolled trial comparing the efficacy and 
safety of iOWH032 to placebo after a cholera challenge in adult  healthy volunteers.  
 SAS version 9.4 or greater will be used for analysis. For descr iptive statistics, continuous variables will 
be summarised by the number of non-missing observations, mean, median, standard deviation, and 
minimum and maximum.  Categorical variables will be summarised by presenting the frequency and 
percent.  Unless otherwise specified, inference such as confide nce interval construction will be 
conducted with two-tailed Type I error level α = 0.05.  No adju stment for multiple comparisons across 
endpoints will be conducted.  All secondary endpoints will be c onsidered as supportive evidence of 
efficacy and will be analysed without any procedures to account  for multiple comparisons.   
 In general, nonparametric analyses or exact methods (e.g., Fish er’s exact test) will be preferred for 
efficacy analyses, with confidence intervals for binary variabl es computed via the Clopper-Pearson 
exact method, and confidence intervals for continuous variables  computed via the percentile 
bootstrap method, using n=10,000 replicates each.  
Primary efficacy analysis will be stratified by blood type stat us (O vs Non-O) as described below. All 
efficacy endpoints will be summarized, by group and by group an d O vs Non-O status, using daily and 
overall summaries, where appropriate. Exploratory analyses will  consider stratification by cohort to 
account for potential differences in challenge inoculum between  cohorts. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 48 of 69 
  
Analysis of diarrheal stool output rate, diarrheal stool volume , cholera-containing diarrheal stool 
volume, and density of cho lera organisms will be supplemented w ith reverse cumulative distribution 
curves.  All data will be provided in listings, in addition to the summa ries described below. 
12.5.2 Analysis of the Primary Efficacy Endpoint(s) 
The primary efficacy endpoint is “Diarrheal stool output rate”,  defined as the total volume of diarrheal 
stools (mL, Grade 3 and above) divided by the number of hours b etween initiation of study product 
dosing and initiation of antimicrobial therapy.  Statistical comparison of the primary endpoint between groups w ill be conducted with the stratified 
(by blood type group) version of the Wilcoxon rank-sum test, th e Van Elteren test.  If a one-sided 
statistical test rejects H
0 and the median is less for the iOWH032 group than for the place bo group, 
the study will have demonstrated that iOWH032 is superior. The hypothesis test will be supplemented 
by a two-sided confidence intervals for the difference in media n diarrheal stool output rate, using the 
percentile bootstrap method, with n=10,000 replicates. See Sect ion 12.5.8 for a description of the 
one-sided alpha levels to be used for testing the primary endpo int. 
 The principal analysis will be performed using the mITT populat ion. If greater than 20% of subjects are 
excluded from the mITT due to onset of symptoms after 48 hours,  the primary endpoint will be 
calculated again including patients with symptom onset after 48  hours. For subjects with symptom 
onset after 48 hours, the time between onset of symptoms and ad ministration of antimicrobials will 
define the denominator used to calculate the diarrheal stool ou tput rate.   Supportive analysis will be 
performed using the per-protocol population.
 
 
Analysis of the primary endpoint will be conducted at an interi m analysis upon completion of 24 
participants, and again on the aggregate data after an addition al 24 participants have completed the 
study. Methods defined in Section 12.5.8 will be used to contro l overall type I error rate at one-sided 
level alpha = 0.025. 
12.5.3 Analysis of the Secondary Efficacy Endpoints 
Secondary efficacy endpoints include a) the proportion of parti cipants with moderate or severe 
diarrhea following cholera challenge defined as ˃3.0 L and ˃5.0  L of loose stools, as well as b) the 
attack rate of any diarrhea following cholera challenge defined  as the number of participants with 2 
or more loose stools (grade 3-5) totalling >200 mL within 48 ho urs or 1 loose (grade 3-5) stool ˃ 300 
mL.  Both endpoints will be computed as the proportion within each g roup satisfying the respective 
definitions, and will be accompanied by exact two-sided 95% con fidence intervals. This will be 
supplemented with corresponding summaries within study arm and blood type group. Statistical 
inference for each endpoint will be conducted with the Cochran- Mantel-Haenszel test, stratified by 
blood type group.  
If a two-sided- statistical test with Type I error rate of 0.05  rejects H
0 and the proportion of participants 
is less for the iOWH032 group than for the placebo group, the s tudy will have demonstrated that 
iOWH032 is superior.  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 49 of 69 
 The AUC of diarrheal stool volume and cholera organisms will be  computed via the trapezoidal rule. 
The secondary endpoints of AUC of cholera-containing diarrheal stool volume, AUC of cholera 
organisms, and peak shedding of cholera organisms (highest cfu counts for each participant) will be 
analysed in quantitative stool culture and will be summarized a nd analysed with methods similar to 
the primary efficacy endpoint, to be further defined in the SAP . 
 Cholera illness during the interval immediately following chall enge and prior to initiation of antibiotics 
will be summarized by group and by blood type group (O vs non O ) within group. 
x Time (hours, post-challenge) to the last unformed stool (grade >=2, overall, as well as by-
grade), will be summarized with Kaplan-Meier methods and compar ed with the log-rank test 
x The total count of loose stools will be summarized as a continu ous variable and compared 
separately for each blood type group with the Wilcoxon rank-sum  test and jointly with the 
Van Elteren test, stratified by blood type group (O vs non O). 
x The presence of fever or vomiting will each be summarized as ca tegorical variables, with 
between-group inference conducted separately for each blood typ e group with Fisher’s exact 
test, and jointly via the Cochran-Mantel-Haenszel test, stratif ied by blood type group (O vs 
non O).  
 
The principal analyses will be performed using the mITT populat ion.  Supportive analysis will be 
performed using the per-protocol population.    Detection of cholera in stool post-challenge will be summarized  overall and by time point using 
categorical methods. Time to cessation of detectable cholera in  stool (hours) will be analysed using 
Kaplan-Meier methods. Additional exploratory efficacy analyses may be identified, and should be 
described in SAP, prior to the interim analysis. 
12.5.4 Safety Analyses 
All safety analyses and demographic/baseline characteristic sum maries will be based on the safety 
population, according to treatment received. 
 
Adverse Events: The summary of AEs will be based on treatment-e mergent AEs (TEAEs) defined as AEs 
which start or worsen following the start of challenge and up u ntil the follow-up visit. 
 TEAE summaries will be based on system organ class and preferre d term assigned to the event using 
the Medical Dictionary for Regulatory Activities (MedDRA). A su mmary table will be presented, by 
treatment group, for the numbers and percentages of participant s with any TEAEs, related TEAEs, 
serious TEAEs, serious and related TEAEs, any severe TEAEs, and  TEAEs leading to discontinuation 
from the study. TEAEs will also be summarized by preferred term /system organ class and severity by 
treatment group. This table will also be presented for TEAEs ca usally related to study treatment 
(defined as those described as possibly, probably or definitely  related to study drug). Tables will also 
include an overall event count by treatment group. All subject- level percentages (solicited/unsolicited 
AEs, etc.) will be supplemented with two-sided 95% confidence i ntervals computed via the Clopper-
Pearson method.  Solicited adverse events collected during the dosing phase will  be summarized by causality and 
severity, using the maximum grade overall.  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 50 of 69 
 Clinical laboratory values will be graded per Appendix D, and a bnormalities for each lab (and overall) 
will be summarized by maximum grade overall and per time point.  A corresponding summary will be 
produced only for those considered to be clinically relevant.  Physical exam abnormalities will be summarized. Clinically rele vant abnormal vital signs will be 
summarized. Abnormal screening ECG results will be summarized.  Continuous summaries of clinical lab values and vital signs, in cluding change from baseline, will be 
computed by group and time point. 
12.5.5 Adherence and Retention Analyses 
Participants who prematurely discontinue from the study will no t be included in analyses/summary 
statistics beyond the time of discontinuation.   
 
Rates of discontinuation and reason for discontinuation will be  summarized in data listings or 
summary tables. 
12.5.6 Protocol Deviations 
Protocol deviations will be summarized by group and listed, wit h classification into major/minor of 
participant-specific deviations completed on blinded data prior  to database lock. 
12.5.7 Baseline Descriptive Statistics 
Demographic data, including blood type, age, gender, height, we ight, BMI, and race/ethnicity will be 
summarized using descriptive statistics by treatment group.  Co ntinuous variables will be summarised 
by the number of non-missing observations, mean, median, standa rd deviation, and minimum and 
maximum. Categorical variables will be summarised by presenting  the frequency and percent. 
 
Prior/ongoing and new concomitant medications will be summarize d (separately) by anatomical-
therapeutic-chemical (ATC) class after coding with the WHO Drug  dictionary. 
12.5.8 Planned Interim Analyses 
Once efficacy data are available from the completion of Cohort 1, an interim analysis of the primary 
efficacy endpoint will be conducted to guide the decision to mo ve forward with Cohort 2. The 
interim analysis focusing on safety and efficacy of the iOWH032  will be partially blinded and will be 
shared with the SRC for a recommendation to the sponsor. Only t he primary endpoint will be 
compared to the boundary values below for purposes of interim a nd final analysis. 
 The following boundary values will be used at the interim analy sis: 
If the one-sided Van Elteren test of the superiority of the dia rrheal stool output rate 
(iOWH032 vs placebo) yields a p-value less than 0.0051 , then the study product will be 
deemed superior to placebo, and the second cohort will not be e nrolled 
If the one-sided Van Elteren test of the superiority of the dia rrheal stool output rate 
(iOWH032 vs placebo) yields a p-value greater than 0.4585 , this will be considered 
evidence of futility (lack of demonstrated efficacy), and the s econd cohort will not be 
enrolled 
In all other cases, the 2
nd cohort will be enrolled 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 51 of 69 
 Due to the nonzero probability of concluding efficacy (under al ternative hypotheses) at the interim 
analysis, the alpha level (type I error rate) for the final ana lysis needs to be adjusted to maintain 
overall one-sided level alpha = 0.025. The threshold to define success on the primary efficacy 
endpoint at the final analysis is one-sided alpha = 0.0238 . 
12.5.9 Multiple Comparison/Multiplicity 
Adjustment for multiplicity for the group-sequential analysis o f the primary efficacy endpoint is 
described in Section 12.5.8.  All secondary endpoints will be c onsidered as supportive evidence of 
efficacy and will be analysed without any procedures to account  for multiple comparisons.  
12.5.10 Exploratory Analyses 
Additional exploratory analyses may be identified, and should b e described in SAP, prior to the interim 
analysis. 
12.5.11 Missing data 
All reasonable measures will be taken to ensure minimal missing  data. Despite this, some data are 
likely to be missing at the end of the study. No imputation is planned for any endpoints in this study, 
and all data will be considered to be missing completely at ran dom. Should observations indicate this 
is not likely to be true for a given endpoint, additional sensi tivity analyses may be conducted, such as 
multiple imputation, to assess the impact of the missing data.  
12.6 Sample Size   
This study is a Phase 2a study to determine the presence and ma gnitude of treatment effect of 
iOWH032 on prevention of cholera sequela after a cholera challe nge.  Data from placebo-vaccinated 
participants in a prior cholera challenge study conducted at th e University of Maryland, including a 
mixture of type O and Non-O participants, demonstrated a mean t otal fluid output of 4448 ± 3178 mL 
over the post-challenge follow-up period(5). Type O participants had a minimum total diarrheal output 
volume of approximately 500 mL and a maximum of approximately 1 1,200 mL, with a roughly uniform 
distribution across this span. For non-Type O participants, the  minimum was approximately 600 mL 
and the maximum was approximately 7,800 mL. The daily rate of d iarrheal stool output between 
challenge and initiation of antibiotic therapy estimated from t hese same data yield a roughly uniform 
distribution between 100 mL/day (both groups) and 2,200 mL/day (non-type O) or 3,000 mL/day (Type 
O). For sample size computation, it was assumed that:  
x The placebo group in the present study would yield daily diarrh eal stool rates uniformly 
distributed between 100 mL and 3,000 mL/day for Type O particip ants, and between 100 
mL/day and 2,200 mL for non-Type O participants 
x Treatment with iOWH032 would yield approximately a 50% reductio n in daily diarrheal stool 
rate, with values uniformly distributed between 100 mL and ½ th e upper limit for the placebo 
participants (1,500 mL/day and 1,100 mL/day for Type O and non- Type O participants, 
respectively) 
x Approximately 40% of participants will be blood Type O, and wil l be equally distributed across 
study arm and study stage 
 
This represents an assumption that all participants will respon d to treatment, which is currently 
unknown. No prior data are available to inform the expected eff ect size, and the hypothesis selected 
here is expected to represent a feasible effect size for an imp actful therapy. Randomization is 
stratified by blood type group (type O vs non-type O) to ensure  balanced randomization, and 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 52 of 69 
 therefore a stratified analog of the Wilcoxon rank-sum test, th e Van Elteren test, is employed for joint 
analysis across blood type group. 
 Participants are to be excluded from analysis if there is lack of evidence of cholera infection following 
challenge, defined as no diarrheal stool output of grade 3 or h igher within 48 hours of challenge. 
Additionally, participants displaying rapid onset of severe cho lera may have diarrheal stool output 
volume truncated due to early initiation of antimicrobial thera py. The use of a rate endpoint, as well 
as the nonparametric test for analysis is expected to yield a r esult that is insensitive to the influence 
of these observations, which are expected to be rare. The distr ibution of diarrheal stool output 
volume and rate is not well-characterized, and cannot be assume d to be normally-distributed based 
on prior data, further implying the need for a nonparametric an alysis. 
 
The primary efficacy endpoint is to be analysed at both an inte rim and a final analysis. Because of 
the multiplicity of testing and accompanying efficacy and futil ity thresholds at the interim analysis, a 
group-sequential framework is employed. Traditional methods for  trial design are intractable in this 
case, due to the anticipated distribution of the endpoint and t he use of stratified nonparametric 
testing for its evaluation. For this reason, a simulation-based  framework was used to simulate data 
under both the null and alternative hypotheses. Power is comput ed as the proportion of simulations 
under the alternative hypothesis which yield a conclusion of su periority at either interim or, given 
that futility is not declared at interim, at the final analysis . Type I error is computed as the 
proportion of simulations under the null hypothesis which yield  the same conclusion, erroneously. 
The simulation procedure was submitted to a constrained optimiz ation routine that selected 
boundary values which ensure overall ≥90% power and type I erro r ≤0.025, simultaneously. Further 
simulations confirmed the adequacy of these boundaries to provi de high power while maintaining 
nominal type I error rate. The boundary values that will be use d at the interim analysis are: 
 
If the one-sided Van Elteren test of the superiority of the dia rrheal stool output rate 
(iOWH032 vs placebo) yields a p-value less than 0.0051 , then the study product will be 
deemed superior to placebo, and the second cohort will not be e nrolled 
If the one-sided Van Elteren test of the superiority of the dia rrheal stool output rate 
(iOWH032 vs placebo) yields a p-value greater than 0.4585 , this will be considered 
evidence of futility (lack of demonstrated efficacy), and the s econd cohort will not be 
enrolled 
In all other cases, the 2
nd cohort will be enrolled 
 Due to the nonzero probability of concluding efficacy at the in terim analysis, the alpha level (type I 
error rate) for the final analysis needs to be adjusted to main tain overall one-sided level alpha = 
0.025. The threshold to define success on the primary efficacy endpoint at the final analysis is one-
sided alpha = 0.0238 . This hypothesis tes t will be supplemented  by a two- sided 95% confidence 
interval for difference in median diarrheal stool output rate, using the percentile bootstrap method, 
with n=10,000 replicates. 
 With the abovementioned boundary values and sample size, the po wer decreases to 70% for a 40% 
reduction in daily diarrheal stool rate and to 30% a reduction of 25% in daily diarrheal stool rate.  
However, and effect size of 50% reduction is expected to repres ent a feasible effect size for an 
impactful therapy.  For the secondary endpoint of proportion of participants with m oderate or severe diarrhea, with 24 
participants per group, and assuming 40% of participants are Ty pe O, adequate power is available to 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 53 of 69 
 detect odds ratios of moderate or severe diarrhea in iOWH032-tr eated participants vs placebo which 
are significantly less than 1, using a Cochran-Mantel-Haenszel test stratified by blood type group, with 
two-sided level alpha = 0.05. For example, if 67% (47%) of the type O (non-type O) control participants 
experience moderate or severe diarrhea, and only 20% (10%) of t ype O (non-type O) iOWH032-
treated participants do (common odds ratio 0.123), then 80% pow er is available to detect a common 
odds ratio < 1. Only a single analysis will be conducted for ef ficacy endpoints other than the primary 
efficacy endpoint, upon collection of data from all participant s included in the experiment. 
 
12.7  Measures to Minimize Bias 
12.7.1 Enrollment/ Randomization/ Masking Procedures 
This parallel group study is randomized and double-blinded to m inimise bias, and includes a placebo 
control arm to enable those effects related to dosing of random ized study treatment to be more 
readily identified.  Participants will be randomized using a 1: 1 ratio to iOWH032 or matching placebo.  
The randomization scheme will be generated by an independent st atistician.  The study site will 
receive one set of randomization envelopes to be stored and use d in the study clinic.  Clinic staff will 
assign these envelopes in sequential order, by envelope number,  to eligible participants.   
 Section 12.7.3 details the procedures for breaking the study bl ind.  
12.7.2 Evaluation of Success of Blinding 
This study is designed as a randomized, double blind, placebo c ontrolled, parallel group study.  As 
such, participants will be allocated to either iOWH032 or match ing placebo.  No specific evaluation of 
the success of study blinding is planned.  Any unblinding will be noted in case report forms.     
12.7.3 Breaking the Study Blind/Participant code 
In the event of a medical emergency, the site PI may require th at the blind be broken for the subject 
experiencing the emergency when knowledge of the subject’s trea tment assignment may influence 
the subject’s clinical care. Prior to unblinding, the site PI i s encouraged (to the extent possible, without 
jeopardizing the subject’s health) to contact PATH Medical Offi cer (or designee) to discuss the decision 
to break the blind. In case of medical emergency, PATH must be notified within 24 hours after breaking 
the blind. The date and reason that the blind was broken must b e recorded in the source 
documentation and case report form, as applicable.  
13 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS 
Source data are all information, original records of clinical f indings, observations, or other activities 
in a clinical trial necessary for validation of the clinical da ta.  Examples of these original documents 
and data records include, but are not limited to, hospital reco rds, clinical and office charts, 
laboratory notes, memoranda, participants’ memory aid or evalua tion checklists, pharmacy 
dispensing records, recorded data from automated instruments, c opies or transcriptions certified 
after verification as being accurate and complete, microfiches,  photographic negatives, microfilm or 
magnetic media, x-rays, and participant files and records kept at the pharmacy, at the laboratories, 
and medico-technical departments involved in the clinical trial .  All information on the Case Report 
Form (CRF) will be traceable to these source documents, which a re generally maintained in the 
participant’s study file.  The source documents will include a copy of the signed Informed 
Consent/HIPAA authorization. The source document data collectio n forms for Screening, Inpatient 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 54 of 69 
 Pre-Challenge to Day of Challenge, Inpatient Post-Challenge, Fl ow Sheet of Stool and Emesis Record, 
Outpatient Visits and Adverse Events will also serve as Case Re port Form (CRF) data collection 
instruments.  
14 QUALITY ASSURANCE AND QUALITY CONTROL 
All clinical trials conducted by Pharmaron are internally monit ored for quality assurance and control.  
Quality Control (QC) and Quality Assurance (QA) procedures are designed to ensure that the site and 
investigator comply with applicable regulations, adhere to the IRB-approved protocol, generate 
quality data, protect data integrity, and safeguard the safety and well-being of study participants. 
The quality plan has the authority to enforce and correct defic iencies in clinical and laboratory 
conduct of a trial.  The QC process involves day-to-day logic a nd edits checks of source documents, 
case report forms, and laboratory documents.  The QA process in volves periodic retrospective audits 
of study records and prospective reviews of clinical operations  and assurance that all research 
required training has been completed as applicable.  These audi ts also involve the review of the 
regulatory file, consent forms/process, eligibility, study prod uct accountability and storage, 
specimen collection, processing, storage, and shipping.  All ob servations are reviewed with the PI, 
coordinator, and Clinical Research Manager; Corrective Action P lans are formulated in response to 
any issue. 
15 ETHICAL CONSIDERATIONS (AND INFORMED 
CONSENT) 
15.1 Ethical Standard 
The investigator will ensure that this study is conducted in fu ll conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects 
of Research of the US National Commission for the Protection of  Human Subjects of Biomedical and 
Behavioral Research (April 18, 1979) and codified in 45 CFR Par t 46 and/or the ICH E6; 62 Federal 
Regulations 25691 (1997).   
15.2 Institutional Review Board 
The local institution must provide for the review and approval of this protocol and the associated 
informed consent documents by an appropriate ethics review comm ittee or Institutional Review 
Board (IRB). Any amendments to the protocol or consent material s must also be approved before 
they are placed into use unless it is in the best interest of t he participants’ safety to implement 
changes prior to approval. In both the United States and in oth er countries, only institutions holding 
a current U. S. Federal-Wide Assurance issued by OHRP may parti cipate.  
Refer to: http://www.hhs.gov/ohrp/assurances/ .   
Prior to enrollment of participants into this clinical study, t he protocol and the informed consent 
form(s) will be reviewed and approved by the appropriate IRB. A ny amendments to the protocol or 
consent materials will also be reviewed and approved by the app ropriate IRB. The responsible 
official for the IRB will sign the IRB letter of approval of th e protocol prior to the start of this clinical 
study. Should amendments to the protocol be required, the amend ments will be submitted to the 
IRB; an IRB letter of approval of the amendment must be obtaine d prior to acting upon the 
amendment in the protoc ol. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 55 of 69 
 15.3 Informed Consent Process 
15.3.1 Consent and Other Informational Documents Provided to 
Participants 
Consent forms describing in detail the study agent, study proce dures, and risks are given to the 
participant and written documentation of informed consent is re quired prior to starting 
intervention/administering study product. The following consent  materials are submitted with this 
protocol: 
x Recruitment script 
x Patient information sheet 
x Informed consent form 
x Study comprehension assessment test 
15.3.2 Consent Procedures and Documentation 
Informed consent is a process that is initiated prior to the in dividual’s agreeing to participate in the 
study and continues throughout the individual’s study participa tion.  Extensive discussion of risks 
and possible benefits of this therapy will be provided to the p articipant.  Consent forms describing in 
detail the study, study procedures and risks are given to the p otential participant and written 
documentation of informed consent is required prior to starting  any study procedure.  Consent 
forms will be IRB-approved and the participant will be asked to  read and review the document. 
Upon reviewing the document, the investigator will explain the research study to the participant and 
answer any questions that may arise.  The participants will sig n the informed consent document 
prior to any procedures being done specifically for the study.  As a part of the consenting procedures 
the participants should pass a written examination (comprehensi on assessment test) with a score 
≥70%, in order to demonstrate their comprehension of this study . If a participant scores at least 
50%, then they will be given one more opportunity to re-test af ter further re-education. The 
participant should have the opportunity to discuss the study wi th their surrogates or think about it 
prior to agreeing to participate.  The participant may withdraw  consent at any time throughout the 
course of the trial.  A copy of the informed consent document w ill be given to the participant for 
their records.  The rights and welfare of the participant will be protected by emphasizing to them 
that the quality of their medical care will not be adversely af fected if they decline to participate in 
this study. 
 
15.4 Exclusion of Women, Minorities, and Children (Special 
Populations) 
This clinical study will include women, adults 18 years of age and older, and all minorities who meet 
the inclusion/exclusion criteria, regardless of religion, sex, or ethnic background.   
15.5 Participant and Data Confidentiality 
Participant confidentiality is strictly held in trust by the in vestigators, their staff, and the Sponsor.  
This confidentiality is extended to cover testing of biological  samples and other testing in addition to 
the clinical information relating to participant. 
The study protocol, documentation, data, and all other informat ion generated will be held in strict 
confidence.  No information concerning the study or the data wi ll be released to any unauthorized 
third party without prior written approval of the sponsor. 
The study monitor or other authorized representatives of the sp onsor may inspect all documents 
and records required to be maintained by the investigator, incl uding but not limited to, medical 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 56 of 69 
 records (office, clinic, or hospital) and pharmacy records for the participants in this study.  The 
clinical study site will permit access to such records. 
Participant identity data will be contained in paper study reco rds which will be kept in a locked file 
cabinet and in a secure electronic database, accessible only to  authorized users at each clinical site. 
The study database will be user-restricted and password-protect ed. The study database will identify 
participants by a coded study participant ID number assigned by  clinical site personnel, thus 
participants will not be identified by name. 
15.5.1 Research Use of Stored Human Samples, Specimens, or Data  
 
x Intended Use: data collected under this protocol may be used to  study cholera and other 
enteric health conditions.  
x Storage: Access to samples stored during the course of the stud y will be limited. Samples 
and data will be stored using codes assigned by the investigato rs. Data will be kept in 
password-protected computers. Only investigators will have acce ss to the samples and data.  
x Tracking: Data will be tracked using a central inventory system . .  
Data collected for this study will be analyzed and stored at th e Pharmaron study site. After the study 
is completed, the de-identified, archived data will be transmit ted to and stored at PATH for use by 
other researchers including those outside of the study. Permiss ion to transmit data to PATH will be 
included in the informed consent. When the study is completed, access to study data will be 
provided through PATH.  
 
15.6 Future Use of Stored Samples 
 
No stool, vomitus, or urine specimens will be stored after the end of the study for future use.  All 
blood specimens collected during the study will be stored, anal yzed, and destroyed within 10 years. 
The informed consent form includes language to allow participan ts to agree for potential future 
research with their blood samples and data related to enteric d iseases. The samples and data used 
for future research will be de-identified and labeled with stud y identification number and not any 
personally identifiable information. A Biorepository Governance  Plan will be maintained by PATH to 
describe the disposition and access to samples being stored for  future research. 
16 Data Handling and Recordkeeping 
16.1 Data Collection and Data Management Responsibilities 
The investigator is responsible for ensuring the accuracy, comp leteness, legibility, and timeliness of 
the data reported. Source documents are maintained for recordin g data for each participant 
enrolled in this clinical study. Study participants’ data colle cted on the CRF during the trial will only 
be identified by participant number.  If, as an exception, it i s necessary for safety or regulatory 
reasons to identify the patient, both the Sponsor and the Inves tigator are bound to keep this 
information confidential. 
All the information required by the protocol should be provided ; any omissions require explanation.  
Each source document and corresponding CRF should be completed and available for monitoring 
and/or collection within a timely manner so that the monitor ma y check the entries for 
completeness, accuracy and legibility, ensure the CRF is signed  by the Investigator, and transmit the 
data to the Sponsor. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 57 of 69 
 All source documents and CRF should be completed in a neat, leg ible manner to ensure accurate 
interpretation of data. Black or blue ink is required to ensure  clarity of reproduced copies. When 
making a change or correction, cross out the original entry wit h a single line and initial and date the 
change. DO NOT ERASE, OVERWRITE OR USE CORRECTION FLUID OR TAPE  ON THE ORIGINAL.  
PATH is responsible for data management activities and will dev elop a Data Management Plan 
(DMP) prior to participant enrollment. The DMP will describe ro les of stakeholders and specific 
procedures to ensure appropriate handling of data at all steps of the data management process, to 
ensure a valid and high-quality database at the end of the stud y, ready for analysis. 
The Investigator or designee must enter the information require d by the protocol onto the CRF 
provided.  The Sponsor’s clinical site monitor will review the CRF for completeness and accuracy and 
instruct site personnel to make any required corrections or add itions. Source data will be entered 
into a Medidata RAVE® data management system, managed by Pharma ron. Medidata RAVE® is a 
secure cloud-based application for building an electronic datab ase that provides a robust audit trail. 
The electronic data capture (EDC) system includes password prot ection and internal quality checks, 
such as automatic range checks, to identify data that appear in consistent, incomplete, or inaccurate.  
Entered data will be verified by an independent monitoring CRO who will query the site for potential 
discrepancies following a review of the source data against the  database for a percentage of the 
data. The site Investigator, or designee, will be responsible f or the resolution of queries and 
appropriate documented changes in the database.  
Automated queries generated by the EDC system are used to flag data discrepancies or 
inconsistencies. The site investigator, or designee, is require d to provide a satisfactory resolution to 
the queries within the EDC system. In addition, the medical rev iewers will also review data for 
medical inconsistencies, which will be raised as manual queries  within the EDC system. The Data 
Manager reviews all the discrepancies to ensure that these are adequately resolved and to identify 
corrective and preventive actions if required. The responsible data manager will perform all 
activities as per standard operating procedures (SOPs) and/or w ork instructions. All study specific 
processes will be described in the DMP. Quality control audits of all key safety, laboratory, and 
clinical data in the database will be made after data entry has  been completed.  Coexistent medical 
conditions, adverse events and other medical events will be cod ed using MedDRA dictionary. 
Concomitant medications will be coded using WHO-DD dictionary. When the database has been 
declared to be complete and accurate, the database will be lock ed for final statistical analysis.  Any 
changes to the database after that time can only be made by joi nt written agreement of the study 
team.  
16.2 Study Records Retention 
 
Study documents should be retained for a minimum of 2 years aft er the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an ICH region or until at least 2 years have elapsed since t he formal discontinuation of clinical 
development of the investigational product. These documents sho uld be retained for a longer 
period, however, if required by local regulations. No records w ill be destroyed without the written 
consent of the sponsor, if applicable. It is the responsibility  of the sponsor to inform the investigator 
when these documents no longer need to be retained. 
 
16.3 Protocol Deviations 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 58 of 69 
 A protocol deviation is any noncompliance with the clinical tri al protocol, GCP, or MOP 
requirements. The noncompliance may be either on the part of th e participant, the investigator, or 
the study site staff. As a result of deviations, corrective act ions are to be developed by the site and 
implemented promptly. 
 
These practices are consistent with ICH E6:  
x 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
x 5.1 Quality Assurance and Quality Control, section 5.1.1  
x 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
It is the responsibility of the site to use continuous vigilanc e to identify and report deviations within 
48 hours of identification of the protocol deviation to PATH. A ll deviations must be addressed in 
study source documents, reported PATH. Protocol deviations must  be sent to Advarra per their 
guidelines. The site PI/study staff is responsible for knowing and adhering to Advarra requirements. 
PATH Medical Officer will be responsible for PATH Research Ethi cs Committee correspondence, 
expedited and other reporting requirements. Further details abo ut the handling of protocol 
deviations will be included in the MOP. 
 
16.4 Publications and Data Sharing Policy 
 
The study sponsor will register this trial on ClinicalTrials.go v in accordance with Section 801 of the 
FDA Amendments Act of 2007. 
 It is understood by the investigators that the information gene rated in this study will be used by the 
sponsor in connection with the development of the product and t herefore may be disclosed to 
government regulatory agencies in various countries.  The spons or (and manufacturer) also 
recognizes the importance of communicating study findings and t herefore encourages their 
publication in reputable scientific journals and presentation a t seminars or conferences, while 
protecting the integrity of the ongoing trial.  Any publication , lecture, manuscripts of the findings of 
this study by any individual involved with the study will be go verned by the procedure outlined in 
the Clinical Trial Agreement.   Within any presentation or publ ication, confidentiality of individual 
participants will be maintained, with identification by partici pant code number and initials, if 
applicable. 
17 Financing and Insurance 
The trial is supported by a grant from .  
 
PATH will provide locally admitted clinical trial insurance for  the payment of any expenses related to 
the treatment of injuries directly attributable to participatio n in this study. 
18 Conflict of Interest Policy 
The independence of this study from any actual or perceived inf luence, such as by the 
pharmaceutical industry, is criti cal. Therefore, any actual con flict of interest of persons who have a 
role in the design, conduct, analysis, publication, or any aspe ct of this trial will be disclosed and 
managed. Furthermore, persons who have a perceived conflict of interest will be required to have 
such conflicts managed in a way that is appropriate to their pa rticipation in the trial. The study 
leadership has established policies and procedures for all stud y group members to disclose all 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 59 of 69 
 conflicts of interest and will establish a mechanism for the ma nagement of all reported dualities of 
interest.  
 
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 60 of 69 
 19 References 
 
1. de Hostos EL, Choy RK, Nguyen T. Developing novel antisecretory  drugs to treat infectious 
diarrhea. Future Med Chem. 2011. 3(10): 1317-25.  
2.  Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, V erkman AS.  Discovery of 
glycine hydrazide pore-occluding CFTR inhibitors: mechanism, st ructure-activity analysis, 
and in vivo efficacy. J Gen Physiol. 2004. 124(2): 125-37.  
3. Weiglmeier PR, Rösch P, Berkner H. Cure and curse: E. coli heat -stable enterotoxin and its 
receptor guanylyl cyclase C. Toxins (Basel). 2010 2(9):2213-29.   
4. Schwertschlag U, Kumar A, Kochhar S,  Ings R, Ji Y, de Hostos E  L, Choy R, Salam M, Khan W 
A, Lin P Pharmacokinetics and Tolerability of iOWH032, an Inhib itor of the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) Chloride Channel, in  Normal Volunteers and 
Cholera Patients. Gastroenterology 2014. 146 (5): Supplement 1,  S-633. 
5. Levin MM, Nalin DR, Craig JP, Hoover D, Bergquist EJ, Waterman D, Holley HP, Hornick RB, 
Pierce NP, Libonati JP. Immunity of cholera in man: relative ro le of antibacterial versus 
antitoxic immunity. Trans R Soc Trop Med Hyg. 1979;73(1):3-9.  
6. Levin MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR . Duration of infection-
derived immunity to cholera. J Infect Dis. 1981 Jun;143(6):818- 20. 
7. Clements ML, Levin MM, Young CR, Black RE, Lim YL, Robins-Brown e RM, Craig JP. 
Magnitude, kinetics, and duration of vibriocidal antibody respo nses in North Americans 
after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145( 4):465-73 
8. Black RE, Levin MM, Clements ML, Young CR, Svennerholm AM, Holm gren J. Protective 
efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit 
of cholera toxin. Infect Immun. 1987 May;55(5):1116-20. 
9. Levin MM, Kaper JB, Herrington D, Losonsky G, Morris JG, Clemen ts ML, Black RE, Tall B, Hall 
R. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant 
techniques. Infect Immun. 1988 Jan;56(1):161-7. 
10. Levin MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, Tall B, Cryz S. Safety, 
immunogenicity, and efficacy of recombinant live oral cholera v accines, CVD 103 and CVD 
103-HgR. Lancet. 1988 Aug 27;2(8609):467-70. 
11. Tacket CO, Forrest B, Morona R, Attridge SR, LaBrooy J, Tall BD , Reymann M, Rowley D, 
Levin MM. Safety, immunogenicity, and efficacy against cholera challenge in humans of a 
typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty 21a. Infect Immun. 1990 
Jun;58(6):1620-7. 
12. Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB,  Levin MM. Onset and 
duration of protective immunity in challenged volunteers after vaccination with live oral 
cholera vaccine CVD 103-HgR. J Infect Dis. 1992 Oct;166(4):837- 41. 
13. Losonsky GA, Lim Y, Motamedi P, Comstock LE, Johnson JA, Morris  JG Jr, Tacket CO, Kaper 
JB, Levin MM. Vibriocidal antibody responses in North American volunteers exposed to wild-
type or vaccine Vibrio cholerae O139 specificity and relevance to immunity. Clin Diagn Lab 
Immunol. 1997 May;4(3):264-9. 
14. Tacket CO, Kotloff KL, Losonsky G, Nataro JP, Michalski J, Kape r JB, Edeman R, Levin MM. 
Volunteer studies investigating the safety and efficacy of live  oral El Tor Vibrio cholerae O1 
vaccine strain CVD 111. Am J Trop Med Hyg. 1997 May;56(5):533-7 . 
15. Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky GA, Shimko J, N ataro JP, Edelman R, 
Levine MM, Giannella RA, Schiff G, Lang D. Validation of a volu nteer model of cholera with 
frozen bacteria as the challenge. Infect Immun. 1998 May;66(5): 1968-72. 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 61 of 69 
 16. Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-dose Live Oral  Cholera Vaccine CVD 103-
HgR Protects Against Human Experimental Infection With Vibrio c holerae O1 El Tor. Clin 
Infect Dis. 2016;62(11):1329-1335. 
17. Rennels MB, Levine MM, Daya V, et al. Selective vs. nonselectiv e media and direct plating vs. 
enrichment technique in isolation of Vibrio cholerae: recommend ations for clinical 
laboratories. J Infect Dis. 1980 Sep;142(3):328-31. 
 
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 62 of 69 
 APPENDIX A: PROTOCOL REVISIONS 
 
Version  Date  Significant Revisions  Ethics/Regulatory Approvals  
1.0 
2.0 
 
 
3.0 
 7/24/2019 
10/30/2019 
 
 
12/23/2019  N/A 
Safety Monitoring, AE definition, 
cholera inoculum preparation 
procedures  
Exploratory endpoint, screening 
stool, Lab normal values, mITT 
description etc.  
  
Advarra IRB, FDA 
 
 
Advarra IRB, FDA 
 
4.0 03/13/2020  Additional topline  analyses  Advarra IRB, FDA  
    
    
    
    
    
    
    
   
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 63 of 69 
 APPENDIX B: SCREENING TESTS  
 
Analyte  Unit  Acceptable Values for Safety Labs:  
White Blood Cell count (WBC)  thou/mcL  3600–11000 (2800–11,000 for African-Americans)  
Absolute Neutrophil Count (ANC) thou/mcL  1500–8000  (1200-8000 for African-Americans) 
Hemoglobin (Females)  g/dL F: 11.0–15.6  
Hemoglobin (Males)  g/dL M: 13.0–17.2  
Platelet count  per mm3 125,000–450,000  
ALT IU/L <50 
AST IU/L <40 
Alkaline Phosphates IU/L 44-147 
Sodium mEq/L 135-145 
Potassium mEq/L 3.5-5.5 
Glucose (nonfasting) mg/dL ≤ 115 
Creatinine (females) mg/dL < 1.6  
Creatinine (males) mg/dL < 1.6  
Creatine phosphokinase (Males 
and females) U/L 22-360 
Albumin g/dL <3.3 
Bilirubin, total  mg/dL < 1.4 (unless known Gilbert’s syndrome,  then <2.0)  
Glucose - urinalysis n/a trace or negative  
Protein - urinalysis n/a ≤ 1+  
Occult blood - urinalysis n/a Small, trace or negative* 
RBC (Females) - urinalysis per hpf 0–4*  
RBC (Males) - urinalysis per hpf 0–4  
Serum β-HCG n/a Negative 
Hepatitis B surface antigen n/a Negative  
Hepatitis C virus ELISA n/a Negative 
HIV n/a Negative 
n/a, not applicable 
*presence is acceptable for menstruating women  
12-lead Electrocardiogram Must not have any of the following, in order to be acceptable:  
x Pathologic Q wave abnormalities 
x Significant ST-T wave changes 
x Left ventricular hypertrophy 
x Right bundle branch block 
x Left bundle branch block 
x A-V heart block 
PATH iOWH032 – v4.0 
13 March 2020  
 
 CONFIDENTIAL Page 64 of 69 
 Analyte  Unit  Acceptable Values for Safety Labs:  
x Non-sinus rhythm, excluding isolated premature atrial 
contractions 
PATH iOWH032 – v4.0 
13 March 2020  
 
 
   Page 65 of 69   APPENDIX C: SCHEDULE OF STUDY VISITS AND EVALUATIONS  
Study visit Visit 1 
(screen)  Inpatient Containment Period Visit 2  Visit 3  Visit 4  
Study Day D-85 to-7  D-1 D 1 D 2 D3 D4 D5 D6 D7 D8 D9 D10 D15±1 D29±2 D 180±14  
Informed Consent √               
Medical history, medications √               
Comprehension Assessment Tool √               
Physical examination √  √h √h √h √h √h √h √h √h √h √h √h √h  
Pregnancy testa √ √              
Vital signs √  √g √ g √ g √ g √ g √ g √ g √ g √g √ g    
Screening laboratoryb 1 8  m L                
12-lead ECG √               
Pre-challenge Stool Sample  √              
Safety laboratoryc  10 mL            1 0  m L    
Eligibility confirmation √ √ √             
Challenge   √             
Blinded Study Drug Administrationd   ( √) (√) (√)            
3-day course of antibioticse       ( √) (√) (√)        
Observe & manage illnessf   √ √ √ √ √ √ √ (√) (√) (√)    
Stool grading and culturesf   √ √ √ √ √ √ √ (√) (√) (√)    
pK analysisi   √  √           
Cumulative  blood volume 18 mL 10 mL  2 mL  2 mL        10 mL    
Solicited AEs 7 days post-challenge   √ √ √ √ √ √ √ √      
Unsolicited AEs   √ √ √ √ √ √ √ √ √ √ √ √  
SAEs   √ √ √ √ √ √ √ √ √ √ √ √ √ 
Concomitant medications   √ √ √ √ √ √ √ √ √ √ √ √ √ 
Interval medical history   √ √ √ √ √ √ √ √ √ √ √ √ √ 
Unanticipated problems (UPs) √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 
a. For females of child bearing  potential, a se rum pregnancy te st will be performed at screening and  one day before challenge  
b. Screening laboratory to inc lude: Complete Blood Count (CBC) for WBC, ANC, Hemoglobin, and Platelets; Chemistry panel for Na , K, ALT, AST, Creatinine, Albumin, ALP, CPK, 
Glucose and Total Bilirubin; Serology for HbSAg, anti-HCV, and HIV; Blood Typing; and Urinalysis 
PATH iOWH032 – v4.0 
13 March 2020  
 
 
   Page 66 of 69   c. Safety laborato ry to include: Comple te blood c ount (CBC) for  WBC, ANC, Hemoglobin, and Platelets; and Chemistry panel for N a, K, ALT,AST,ALP, Creatinine, Albumin, and Total 
Bilirubin, CPK, Glucose 
d. Blinded therapeutic dosing  will start at the onset of sympto ms or by 48 hours after ingesting  the cholera challenge inoculu m.   
e. A 3-day course of antibiotics will be initiated upon satisfy ing the criteria for severe cholera diarrhea or approximately 4  day post-challenge, whichever is earlier 
f. The observation and management of cholera illness (includes measurement of vomiting) and stool grading and stool cultures a re intended to be performed throughout the post-
challenge inpatient period, until discharge criteria are satisf ied. For the duration of diarrhea, the participant will be requ ested to provide a urine specimen from every void that they 
experience; the specimen will be tested for urine specific grav ity. In case of IV fluid replacement, serum electrolytes, BUN, and creatinine will be measured.   
g. Vital signs will be measured at least 3 times daily (approxi mately every 8 ±1 hours). Vital signs will also be measured eve ry 4 hours when a participant has a fever ≥ 39 qC 
(102.1qF), until the participant has 2 consecutive temperatures of ≤ 3 8qC (100.4 qF). On Day 1, including the pre-challenge vitals assessment, th ere will be 4 vital signs 
assessments (1x pre-challenge and 3x post-challenge). 
h.  Focused physical examination at the discretion of the physi cian 
i. pK plasma samples for the levels of iOWH032 will be collecte d  7±1 hours after the first and last dosing in all participant s 
 
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 
   Page 67 of 69   APPENDIX D: CLINICAL SAFETY LABORATORY TOXICITY SCALES 
Test Mild 
Grade 1 Moderate 
Grade 2 Severe 
Grade 3 Potentially Life 
Threatening Grade 4 
WBC, increase 1.1 – 1.5 xULN 1.6 – 2.0 xULN 2.1 – 2.5 xULN ≥ 2. 6 xULN 
WBC, decrease* 1.1 – 1.5 xLLN 1.6 – 2.0 xLLN 2.1 – 2.5 xLLN ≥ 2 .6 xLLN 
ANC decrease 1.1 – 1.5 xLLN 1.6 – 2.0 xLLN 2.1 – 2.5 xLLN ≥ 2.6  xLLN 
Hemoglobin decrease 1.1 – 1.5 xLLN 1.6 – 2.0 xLLN 2.0 – 3.0 xLL N >3 xLLN 
Platelet count 1.3 – 1.5 xLLN 1.6 – 2.0 xLLN 2.0 – 3.0 xLLN >3 xLLN 
Glucose   
Nonfasting, High 116-160 161-250 251-500 ≥ 500 
Glucose, Low 55-64 40-54 30-39 < 30 
Sodium, low 132 -134 130 - 132 125 - 129 < 125 
Sodium, high 146 – 148 149 - 150 151 - 152 > 152 
Potassium, high 5.6 – 5.8 5.6 – 6.1 6.2 – 6.5 > 6.5 
Potassium, low 3.3 – 3.4 3.1 – 3.2 2.9 – 3.0 <2.9 
Creatinine* 1.1 – 1.5 xULN 1.6 – 2.0 xULN 2.1 – 3.0 xULN > 3.0 xULN 
AST (SGOT) 1.6 -.2.5 xULN 2.6 – 4.0 xULN 4.1 – 10.0 xULN >10 xU LN 
ALT (SGPT) 1.6 -.2.5 xULN 2.6 – 4.0 xULN 4.1 – 10.0 xULN >10 xU LN 
Alkaline Phosphatase 1.6 -.2.0 xULN 2.1 – 3.0 xULN 3.1 – 10.0 x ULN >10 xULN 
Total Bilirubin 1.2 -.1.5 xULN 1.6 – 2.0 xULN 2.0 - 4.0 xULN >4  xULN 
ULN = upper limit of normal range 
LLN = lower limit of normal range 
*if the baseline is outside of the  reference range (e.g., Afric an-American acceptable value), then relative changes 
to the baseline value will be evaluated for toxicity 
 
  
PATH iOWH032 – v4.0 
13 March 2020  
 
 
   Page 68 of 69   APPENDIX E: REACTOGENICITY AND SOLICITED ADVERSE EVENT TOXICITY  SCALES 
Grading of Stool Consistency  
normal stool  loose or diarrheal stool  
Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Well formed;  
does not take the 
shape of the 
container Soft;  
does not easily take 
the shape of the 
container Thick liquid stool; 
easily takes the 
shape of the 
container Opaque watery 
diarrheal stool Clear watery or “rice 
water” diarrheal 
stool 
 
Diarrhea Severity  
Mild Moderate Severe 
2 or more loose stools of ≥ 200 mL 
within 48 hours 
or 
a single loose stool of ≥ 300 mL Cumulative loose stools of ≥ 3 liter Cumulative loose stools of  ≥ 5 liters 
 
Objective 
Reactogenicity Mild 
Grade 1 Moderate 
Grade 2 Severe 
Grade 3 Potentially Life 
Threatening 
Grade 4 
Diarrhea  (refer to table above ) 
Requires 
hospitalization Vomiting (episodes/24 hour)  1-2 3-4 ≥ 5 
Fever, °C (°F) 38.0 – 38.4  
(100.4 – 101.1) 38.5 – 38.9  
(101.2 – 102) ≥ 39  
(≥ 102.1) 
Tachycardia, bpm  101 - 115 116 - 125 > 125  
Systolic Hypotension, mmHg  85 - 89 80 - 84 < 80  
 
Subjective Reactogenicity, 
includes: abdominal 
pain/cramping, malaise, 
nausea, anorexia, arthralgia No interference 
with activity Some interference 
with activity Prevents daily 
activity Requires 
hospitalization 
 
 
 
PATH iOWH032 – v4.0 
13 March 2020  
 
 
   Page 69 of 69   APPENDIX F:  EXAMPLES OF SUBSTRATES THAT ARE METABOLIZED BY CYP2C9 
 
Drug name  Class  
x Irbesartan  x Angiotensin II blocker  
x Losartan  x Angiotensin II blocker  
x Phenytoin  x Antiepileptic  
x Cyclophosphamide  x Alkylating agent  
x Tamoxifen  x Anti-estrogen  
x Fluva statin  x Statin  
x Celecoxib  x NSAID  
x Diclofenac  x NSAID  
x Ibuprofen  x NSAID  
x Lornoxicam  x NSAID  
x Meloxicam  x NSAID  
x Naproxen  x NSAID  
x Glibenclamide  x Sulfonylurea  
x Glimepiride  x Sulfonylurea  
x Glipizide  x Sulfonylurea  
x Tolbutamide  x Sulfonylurea  
x Warfarin  x Anticoagulant  
 
   